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aOOTER I

'!he primary qoal of this dissertatiai research has been to

determine the potential role of interleukin 1 (IL-1) in the development of protective inm.me responses to an experimental lyitplana. '!his
biological response ll'Odifier (BRM) is considered for study because of
its many known intmunoregulatory roles (64,78),

incl~

the ability

to augment the inm.me response in defined antigenic systems (285,
312).

However, no previous reports have den¥:>nstrated a direct role

for IL-1 in the develcpnent of inmmity to experimental neoplasia.
'!he experimental tunw:>r JOOde1 enployed in this study is the Eir4
lyzrphana which is syn_;eneic in C57Bl/6 mice ani results in high

llk)rtality (39,100).

In this system, mice can be protected f:ran a

nonnally fatal dose of the weakly inummogenic Eir4 lynphama (101) by
local administration of Cocynebacterium paryum ( 183) •

However, these

animals show no deronstrable tun:>r imrm.mity since they will succumb
to a secoIXl challen;re of the tunw:>r.

It has been the

study to determine whether administratiai of IL-1

p.irpose

of this

can enhance anima1

survival or augment the developnent of imrm.mity to the Eir4 lyitpnna.
'!he remaining objective of this :research was to assess the cx:rapart-

ments of the imnnme system which may be m::xiul.ated by IL-1 leadin:j to
the establishment of tunw:>r imrm.mity.

'Ib accomplish this qoal, in

vitro analysis of splenic ani lymphatic tissues of treated anilnal.s
has been perfonned to assess a possible mechanism( s) by which IL-1
1

2

may m::xiulate the imm..me response to the Eir-4 lynphana.

Several

inum.me correlates likely to be associated with the developnent of

ttnoor immunity ani, therefore, urmr scrutiny in this project, were
Eir-4 ttnoor specific cytotoxic T cells, natural killer cells {NK) , ani
hunmal antibody response to the Eir-4 lynphana.

Also, possible

m::xiulation by IL-1 of lyqiloid pcp.1].ations ani their proliferative
responsiveness to the Eir-4 lynphana were investigated.

All of these

inmm:>logical parameters have been reported by other investigators to
be augmented by IL-1 am may urmrlie the mechanism by which IL-1

leads to the augmentatioo of turoor imnamity in the Eir-4:C57Bl/6

experimental no:lel.

CHAPI'ER I I

A.

Adjuvant Effects of Coeynebacterium paryum

over

the last twenty-five years, a wide variety of immunostim-

ulants have been shown to effect the growth of synJeneic transplantable tunm's in mice.

startirg in the early 19608 with

zyioosan

(yeast

cell walls) (233) arxi Bacillus calmette-Guerin (ED;) (231), this list
of inm.mostimul.ants has been exparxied to inclu:ie viable bacteria,
bacterial by-products, nonviable bacteria arxi chemically defined
~

(17).

'!he first Wication that

~

paryum would be<xme an :i.nportant

research tool as an .illm.mological stinulant was dena1strated by
Halpern et al. in 1964, when they fa:all

c.

paryum to be a potent

stinulator of the reticulo-emothel.ial system ( 109) • Many investigators have since verified these observations (123,243,286,294) with

c.

parvum treated mice

showinJ

increases in liver arxi spleen weights

(5,109,188,197,228) as well as an increased ability to clear intravenously injected cartx>n.

c.

parvum has been shown to exert adjuvant

effects on antibody production, in:iuction of delayed type hypersensitivity (5,25,223), arxi may be satisfactorily substituted for the
mycobacterial canponent of F.reurd's cx:arplete adjuvant {223).

c.

parvum treatment enhances protection against protozoal (226) , viral

(143) arxi bacterial infection (3) , as well graft-versus-host disease
(122).

'!here is abumant evidence to Wicate these effects are
3

4

attributable to augmentation of macrophage function (304).

Aside

from enhanced macrophage function, subcutaneous (307) arrl systemic
( 62) administration of

c.

parvum stimulates macrqtlage colony pro-

duction by bone marrow cells, enhances proliferation of granulopoietic cells, and increases the percentage of ncnlifferentiated
cellular fo:nns in the bane marrow (18,262).
Treatment with

c.

growth of subcutaneous

pa:rwm has also been shown to retard the

am peritaleal.

tuna:s in mice (30' 107' 198' 270'

313) • 'lliere is lmlCh S\JRX)rt for the view that macrqilage stbnlation
is the mechanism responsible for the bacterial suspensions• effec-

tiveness in enharx:irq the host's defence against neoplastic disease
(162).

Evidel'lce has .iniioated that augmentation of NK activity is a

potential mechanism of

~

parwm antituioor activity (200) , altllolgh a

mre recent report has dena1strated suppression of NK activity by the
bacterium (86) • 'lhe role of the macrqtlage in the expression of
inmamity to tuna:s was initially described by st\:dies in· which peritoneal macrophage cell suspensions, taken fran inmmized dooors, were

able to exert suppressive effects on syrqeneic tuioors in mice (232) •
'Ihese macrophages were also fami to inhibit the growth of tuioor

cells in yiY:Q (15).

Macrophage mediated tuioor cell killin;J has been

shown to be a property of highly activated macrqilages (139) • Peritoneal macrophages, i?Dioed by irritants such as thioglyoolate,· appeared to be partially activated showin;J increased adherence

am pino-

cytosis (188) • However, these macrophages did not becane cytotoxic
for tuioor cells until fUlly activated with various bacteria or erxiotoxin (37) •

Similarly, macrqtlages obtained fran

c.

parvum treated

5

anilllals, When implanted either subcutaneously or intraperitoneally
(i. p.) with m.irine fibrosaroana 'tunK:>r cells, caused a significant
reductiai in 'tunK:>r growth (246).

'Ihese macrqilages, When incubated

in y1:Q;;:Q with syn:Jelleic 'tunK:>r cells, also demnstrated cytostatic
(108) as well as cytotoxic activity for 'tunK:>r cells (16).

Since both

nude (248,315) arxi germ-free mice (275) dem:Jnstrate equal anti'tunK:>r

effectiveness, it appeared that this augmented inumme functiai was a

direct result of

macrqha~

parvum interactiai.

Additiaial evi-

dence implicated the naiocytejmacrcplage precursor as the target cell

for the anti'tunK:>r effect of
mice shortly before

~

c.

parvum.

Whole body irradiatiai of

parvum injectiai pnwents the develqment of

resi.sta?x:le to tumr challerge, whereas irradiatiai after treatment
oanpletely

~the

failed to abrogate the

c.

hun¥:>ral

response to

c.

parvum (30)' bit

parvum anti'tunK:>r effect (30,200).

'!his

suggests that the relevant cell arose fran a radiosensitive, rapidly
diviclirq precursor whose mature camterpart was radioresistant.

'!his

is consistent with the characteristics of the ioonocyt.ejmacrqi'lage

cell (18) •

Cctrpilatiai of this data has lead to the cxn::llusiai that

the activated macrqi'lage is the CX111t1L>11 mediator of biological effects

of

c.

parvum (29) •

Although

c.

parvum has been used as an inmrunotherapeuic anti-

carx::er agent, the oanponent(s) of this organism responsible for these
activities has not yet been identified.
ical treatments ai the pat:eooy of

c.

'!he effects of varioos chem-

parvum extracts have suggested

that the active oanponent is cartxilydrate in nature (4,40,250,258),
bit may require oanplete cell integrity for full activity (40) since

6

purified cell walls retain antigenicity, :rut do not retain antitunm'
activity (257) •
Althalgh macr:qi1age activaticm may play an inportant role in
tunor rejecticm, these chemical stuiles have shown that cytotoxic

macrq:hages do not appear to be sufficient for the overall antitum:>r
activity

of~

Peritoneal exlX!ate cells frail mice

parvum (40).

treated with the whole organism or the "light residue" (primarily
cell walls am cell walls oontaininJ protoplasm) were highly activated, as deronstrated by their ability to nonspecifically kill tunor
cells

.in~.

However, \totlen the "light residue" was treated with

metaperiodate, which redlices au:Dahydrate content of the residue, the
high macr:qi1age activatin;J prq>erties were maintained, :rut the antituioor activity diminished significantly.

'lhese results suggest that

macrq:hage activaticn is not the only property of
to iniuce full

c.

parnnn require:i

.in vivo antitunm' activity (40) •

It was noted that followin;J systemic injection (intravenous) of

c.

parnnn in mice, there was widespread proliferation, redistribution

am m:>bilization of lynpioid cells (42) with associated splencmegaly,
hepatamegal.y am increased lung (5) am lyrrph node (42,188,197)
weights.

on the other bani, there is little charge in spleen am

liver weights followin;J subcutaneous injection of

c.

parnnn, although

there is an enlargement of lyrrph nodes drainin;J the subcutaneous

injection site (270,294), with an associated increase in lynpiocyt:e
cell number in the drainin;J nodes (51).
Investigaticm of this

~

lead to the deloonstraticm of

c.

parvum mediated lYJl'Ploid m:>bilizaticm
parvum mediated adjuvant activity in

7

mice as de.nalst.rated by an anplification in the antilxxfy response to
both thynus depenient IgM-IgG responses (24,130,305) an:i the thynus

iniepeDjent IgM response (60,123,130,302).
~

I.ocal adjuvant effects of

paryum have been shown When the injection of sheep red blood cells

admixed with .C.:. paryum increased the number of direct plaque formirg

cells in drainin;J lynph nodes (201) •
of antigen to ly.trplocytes seen by

c.

Enhanced antigen presentation

parwm stimulated macrq:hages

(230,307) may explain these lynphocytic stimulatoey effects of

c.

parvum.
T cell responsiveness may be stim.ll.ated or inhibited, depemin]
on the route or

c.

paryum administration.

Systemic

c.

parvum treat-

ment is usually associated with depression of cell-mediated .iJmllne

responses (7 ,272), possibly due to an effective depletion of sensitized cells traR;led in the

c.

parvum stim.ll.ated spleen (272).

on

the

other hard, enhancanent of delayed type hypersensitivity (mH) results after subcutaneaJs injectiai with a wide raBJ8 of ~ parvum

doses (176.271,275,294).

'!he activatiai of macrqilaqes in regional

lynph nodes ag;>ears to modulate the differentiatiai an:i claial.ization
of neamy T cells, with the dani.nant effect bein:j the inhibition of
the qeneratiai of specific T suppressor cells (176).

'Iherefore, the

increase in ioonocyte numbers (18) an:i furx::tional activity (93), both

in accessory cell function an:i lyirphocyte subset modulation, may
augment antigen presentation an:i lynphocytic responses at the site of
macrqi'lage activation.

SUdl mechanisms may mediate the turoc>r inm.m-

ity associated with .C.:. parvum therapy.

8
In nurine systems, the efficacy of

c.

parvum antitumr therapy

has varied greatly depeMirg on several parameters (201), many simi-

lar to the parameters mentioned earlier in this review reganiin;J ioore
general JOOdulatian of illmlrv:>loqical responses.

therapeutic parameters to oonsider

~

Several .inp:>rtant

utilizirg this bacterial

agent are the rcute of injection (201), the size
tumr (52,201), the

am

locatiai of the

anomt of bacteria injected (28,223),

am the

imnumogenicity of the tumr in the host-tunm' no:1el (17 ,245).
din;J on the tumr no:1el en-ployed, systemic adminstration of

c.

Depenparvum

has been shown to be an effective therapeutic agent when sirgle doses

were given f:ran one week prior (30,270) to two weeks (165) after
tumr challen]e.

c.

parvum therapy was also effective when

tum::>r/

bacteria admixtures were injected simultaneously (248,295).
Against established tumrs, systemic

c.

parvum treatment is

JOOSt effective against small tunm' masses when injected soon after

tumr inoculation;

multiple~ parvum

in::reased effectiveness (199,286).

doses have generally not

Althoogh tunor regressions have

been achieved with intravenous therapy, this type of effect is not

usually attainable with poorly inummogenic tumrs (199) •
IDcalized tunor therapy, with direct injection of
into growirg solid tu:mr, have resulted in oc:m:plete

c.

parvum

am permanent

regressions in many different tunx:>r m::xiels (33,106,163,255,294).

In

sane cases, metastasized tun¥:>r have been shown to regzess as well
(163, 165).

SUbcutaneous injections of

c.

parvum at sites distant

f:ran the t.um::>r usually have minimal effect on tum::>r growth, whereas

marked inhibition is seen after injection near the region of t:uJoor

9

growth (271, 314) •

Unlike systemic treatment, which

a~

to favor

the generation of n:mspecific effector mechanisms (i.e. activate:i

macrophages (234,270), natural killer cells (229)), intralesional

c.

parvum therapy ai;pears to generate T cell mediate:i antituioor inm.mity

since this antituioor action requires the preseooe of a fUnctional T
cell system (28,80,296,315).

Animals treate:i in this fashion are not

only able to regress the treate:i tunor lesion, but also regress untreate:i blroc>rs at distant sites which are in early stages of development (202).

Rejection of distant site tuioors has been associate:i

with the augmented production of cytolytic T cells in the lynph rxxies
Animals, which

drainirq the site of therapeutic injection (202).
have regressed their tunDrs after intralesialal.

~

parwm therapy,

are subsequently able to specifically reject a similar tunDr ilrplant

(273,295)

am possess

T cells capable of passively transferrinj tunx:>r

resistance to unimna.mized imividuals (295,296).
Mice, which have rejected tunDrs that have
cells admixed with
(164).
again

c.

parvum, are similarly

am

devel~

fran tuioor

specifically imnune

However, the ability to irxiuoe T cell specific tuioor inm.mity

awears to

(80,249).

be llldte:i

to the

ioore

highly ilrm.ln:lgenic blroc>rs

Nonspecific mechanisms appear to protect animals fran

weakly inmmogenic tuioors followirg intralesional

c.

parvum therapy,

consequently animals sw:vivinJ a weakly imnrunogenic tuioor challerge
are unable to successfully sw:vive a secarxl, identical tuioor chal-

lerge.
'!he Eir-4 lynphana, the tuioor no:ie1 enployed in this study, is

an exanple of a weakly i.mmurx:>genic tuioor (39,100).

'!his tuioor is

10
:refractory to inmmoadjuvant therapeutic aqents such as viable
lf{OC!bacterium bovis, :ea;, am starmrd :regimens of nawiable
parnnn (94,289).

~

More riqoroJS ad.juvant therapy protoools with

c.

parnnn (183) am Blastatr/OeS dentlatitidis (190) have enabled animals

to respotXl to the Eir-4 l:yitplana yieldin;J high sw:vival rates followrin;J tuioor chal.let)le.

HoiMver, animals sw:vivin] this initial 'blloor

c:hallen;Je are unable to dem:lnstrate 'blloor specific immunity upon Eit-4
:rechallen;Je (183).

'lhese results are markedly different when highly

inummogenic tunm' nv:xiels are treated with adjuvant type immunotherapy, where the develq:ment of tunm- specific immunity is seen in protected animals (174,202).

'!he lack of an effective 'blloor inmu.me

response, seen in animals protected by immunoadjuvant therapy fran
weakly immunogenic t.uro:rs like the Eir-4 lyitplana, suggests that this
therapy m:xiel may serve as an effective system to assess other means
of .iJmmmaoodulation which may lead to concomitant t.uror inummity.
B.

'!he Biology of Interleukin 1
I!r-1 is a honnone-like protein which appears to play many roles

in the inflanunatory am inmu.me :responses (64, 78).

Table 1 briefly

lists many of the wide range of attrib.Ites attributed to IIr-1, sane
of which will be discussed in m:re detail later in this review. original inuuunologic studies described I!r-1 as a soluble product :released
fran activated macrcpmges (90) capable of co-mitogenic stiJra4ation

of thyioocytes (89).

HoiMver, I!rl has been redisoavered several

times due to its nlll.tiple biological actiC11S.

'!he original disoovery

of such a host derived subst:aro! occurred in the late 1940S when
fever was initiated by a soluble factor produced am :released by

11
activated peritoneal exudate cells, canprised predaninantly of neutroJ;hlls (20).

am

'Ibis substan:::e was called granulocyte pyrogen,

later erxiogenoos

pyrogen (EP) , when it was fami that this substance

accounted for the febrile associated with bacteria, erXiotoxin
IOOSt other exogenaJS pyrogeni.c materials (9,69).
(MP) (298); B cell activaticm, differentiaticm

antil:xxly p:roducticm

.in vitro

am

other tenns used to

am

enharament of

by B cell activation factor (BA:F) (308),

B cell differentiaticm factor (BDF) (118) or T cell replacirq factor

Table 1. Actions attributed to 100110CY'te derived IIr1.
General process

am

target cells

Antituioor activity
tuJOOr cells
natural killer
mac:rq;Xlages

Growth arxi differentiaticm

T cells
B cells
f ibrablasts

Inflamma.ticm
neutrqnils
bone-mar.t'Olli
macrophages

Activity

directly cytostatic arxi cytolytic

augmentaticm of cytotoxicity
enhanced lysis of tuioor targets
lynpiokine production am release
proliferation am differentiation
proliferation

chencl:axis, degranulaticm,
release

fibroblasts
synovimn
erdothelimn

hepatocytes
Tissue catabolism
skeletal mscle

FG release, ch.er!otaxis
FG am collagenase release, growth
ro am collagenase release
FG release
secretion of acute-P'lase reactants,
control of plasma divalent cations
proteolysis
:resorption

osteoclasts

bone

c.homrocytes

cartilage breakdown

Central :nervous system

hypothalamus
unknown

fever iniucticm
sleep iniucticm

l2

('IRFm) (119)

I

arr:i hel:per peak-1 (HP-1) (145) respectively.

nuch collaborative study of these Dn>kines, it became

After

awarent that

these activities arr:i associated acronyms were actually different

biologic facets of a sirr;Jle biochemical family of m:>lecules.

'Ihere-

fo:re, IL-1 was introduced into the n:::manclature to elllninate confUsicm arr:i

distin:Jui.sh

this m:mokine fran other inm.Jnoregulato:cy

llX)lecules (1).
1.

'lhe Biochemisb:y of IIrl

'Ihe polypeptide nature of IL-1 was shown by enzymatic digestion

with a variety of proteases (269) am loss of activity foll0t1irr:J

arginine residue nOOification (206).

'Ihe possibility that IL-1 is a

glycoprotein remains unresolved, although there is no direct evidenc.e
that cai:Dohydrate :residues are present or essential for IL-1 bioactivity (147 ,204) •

Early estimates

~

IIrl were often oonfusirr;J an:i oontradicto:cy.

the :nolecular weight of

Part of this prct>lem

arose fran the m:>lecu.lar weight het,en)geneity seen fran the intracellular arr:i extracellular form of IL-1 (98) • All reports cannot be
explained by this variatiai si.ral m:>lecillar weight species ran;iin;J

fran 60 to 250 k:ilodaltons (kd) have been reported for both intracel-

lular arr:i extracellular foDllS of IL-1 (211,278,292).

It is likely

that these IL-1 species :represent either aggregates with contaminatin;J proteins or aC}'P:egates of the IIrl m:>namer resultin;J

f~

mixed

disulfide bridges between free cysteine :residues (64) • 'Ihe possibility of a high m:>lecular weight protein carrier for IL-1 may also
explain these sporadic results; however, no evidence for such a carrier has been presented.

several investigations have shown that IL-1
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activity may reside in polypeptide cleavage products as small as 2 kd

to 4 kd in size. A 4.2 kd peptide, which co-purified with PIF fran
plasma of febrile human patients, exhibited biochemical dJaracteristics an:i bioactivity of IL-l (67).

Also, IL-1-like peptides rarg-

il'Xl frail 2 to 4 kd have been fain:! in human urine which retain a
port.ion of their bioactivity (142).
~resistance

269).

'1hese reports may explain the

of IL-1 bioactivity to certain proteases (204,

Only after further purification an:i biochemical dJaracteriza-

tion can the relaticnship of these low DDlecular weight JOOlecules be
oc:mpare

to natural or recanbinant forms of IL-1.

'lhe purification an:i biochemical dJaracterization of IL-1 has

proven to be a difficult task.

unlike many other circulatil'Xl hor-

m:mes, IL-1 is not stored in any glan:i or tissue; an:i

when produced

usil'Xl in yjj;;m superiniuction protocx>ls, only low piocm::>lar quantities are obtained (238).

'lhe production of large quantities of

murine IL-1 by a phol:bol myristate acetate (IMA) stinulated, cloned
macrophage cell line, P388Dl, (156) alle7Ned for its purification to
haoogeneity (208) •

'1he purified murine product dem:mstrated a JOOle-

cular weight of 14,000 an:i, as reported previously (84,210), exhibited microcharge heterogeneity with isoelectric points (pI) of 4.9,
5. o an:i 5 .1.

More recent methods of IL-1 purification, utilizi!'Xl

immunoaffinity procedures with a heterologous antiserum prepared in
goats against murine IL-1 (207), have given a lll.1Ch higher yield of
purified IL-1, thereby

all~

JOOre detailed studies of the protein.

Seven discrete species were isolated upon elect:rqiloresis of this
material with each species havi!'Xl a different JOOlecular weight rarg-
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inq fran 13 to 17 kd as analyzed in a seoorrl dimension by sodium clodecyl sulfate polyac:rylamide electrqiloresis (SIS-PAGE) •
Farly research characterizinq partially pirified human IL-1
:reported a variety of mlecular weights generally in the 11, ooo to

16,000 kilodaltai rarqe (27,157,292).
tion of II.r-1 secreted fran human

High yield methods of produc-

peri~

blood macrophages stimu-

lated with heat killed, formalin-fixed st:.ai;ilylococcus au:reus umer

serum free oorxlitions allowed for the pirification to haoogeneity of
human II.r-1 with a high yield of biological activity (149).

Purified

by ion excllan;Je chranatogra~y arrl affinity chramatogra~y on Procion
Red agarose, the human IL-1, like its 11D.lrine CXJUllterpart, also exhib-

ited microdlarge het:ero;Jeneity with foor dla:tqed species havinq isoelectric points rcm;Jinq fran 6. o to 4. 9.

'lhese

values are sanewhat

lower than that observed for human IL-1 by other investigators (153);
however, these other reports analyzed sanples cxmt:ainirq other pro-

teins which may have influenced the iso-electric point for IL-1 by
fonnirg cxmplexes (149).

Analysis of the pirified human II.r-1 by two--

dimensional. electrcpioresis-electrofocusinq qels dEm:>nstrated all
foor charqed species have an identical :mlecular weight of awroxima.tely 17, 500.

'!he presence of ail.y cna :mlecular 'Weight species in

this preparation was prci>ably due to the serum-free culture oorxli-

tions.

II.r-1 exhibits llllltiple apparent :mlecular weights in the

presence of serum, lllOSt likely due to a reversible association with

high mlecular weight serum carponents (244,292).

Ccmplete amino

acid analysis irrlicated an abumance of acidic residues in agreement
with the low isoelectric point.

No cysteine residues were fourxi,
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which was not sw:pris.in; consider.in; IL-l activity is unaltered by
reduc.in; agents.

No gl11CX')S8Dline or galactosamine was foom.

'lhere-

fore, it is unlikely that IL-l is a glyooprotein (149).
'!he t.remenb.ls poten::y of this protein has been denalstrated on

the basis of PJrification data.

Purified Dllrine IL-l, as dena1stra-

ted by Mizel (208) , has a specific activity of l x 106 U/llr;J protein.
'Ihus, l U/ml Dllrine IL-l is equivalent to a D:>lar mx:ientration of
7 x lo-ll M.

Purified human IL-1 produced by D:>l'lOllUClear cells

showed an even greater specific activity of 3.2 x 108 U/llg protein,

with 1 U/ml of human IL-1 equivalent to a 1.8 x io-13 D:>lar concentration (149) •
IL-l mediates a diverse ran]e of biological activities, includ-

.in; stimulation of thyno::yte proliferation via in:luction of interleukin 2 (IL-2) release (159,281), stinul.ation of B cell maturation
arxi proliferation (97,118,259), augmentation of NK activity (61),

fibroblast growth factor activity (268), iniuction of acute

~

reactants via stimulation of hepatocytes (287) , arxi stimulation of
p:rostaglamin arxi oollagenase release fran synovial cells (206) as
well as fever (261).

'lherefore, the question arises:

can all these

activities reside in a sirqle protein, or is there a family of interleukin l's, each with separate or overlapp.in; functions?

To clarify

these issues, several D:>lecular biology laboratories have attenpted

to clone the genes responsible for IL-l activity.
2.

'!be Molecular Biology of Interleukin 1

Recently, several laboratories have isolated JDJrine arxi human
carplementazy WAs ( cmAs) encodi.rg proteins with characteristic IL-l

16
activity.

'!WO basic strategies have been utilized

to screen macro-

};ilage ct.NA libraries in order to obtain cloned genes for which translatioo products will encode for IL-1-like ioolecul.es.

Macrqilage ct.NA

clones were hybridized to macrophage RNA, arxi RNA isolate:l fran this

process was injected into

.in vitro translation

resultant product assayed for IL-1 activity.

systems with the

'Ihe

seoom procedure

utilized an oligonucleotide probe constructed on the basis of amino
acid sequence analysis of highly p.n-ified human IL-1.
'Ihe nucleotide sequences of the first two ct.NA clones codin;1

for murine (167) or human (13) IOOnOcyte IL-1 code for polypeptide
precursors of 269 arxi 270 amino acids respectively.

'Ihe preclicte:l

primary translation products fran these clooes (inferred fran ct.NA

sequence analysis) would yield proteins of 31,026 arxi 30, 747 daltons
respectively.

'Ihis data stm:gly SUWorts earlier l«>rk identifyirg

the production of a high JOOlecul.ar weight intracellular form of IL-1

which was thought to be the precursor form of the 13, 000-11, ooo
dalton mlecul.ar -weight IL-1 ioolecul.e isolate:l extracellularly (211,

298).

Al.thaigh the 33,000 dalton murine IL-1 was the predaninant

intracellular form, arxi the 17,000-19,000 dalton IL-1, the predaninant extracellular form; the 33, ooo ioolecul.ar -weight peptide was seen

in the culture supernatant& imicatinj that IL-1 may be secreted as a
33, ooo ioolecul.ar weight polypeptide arxi then rapidly converted to
lowrer ioolecul.ar weight forms by macrqilage derived proteases (98).

'lllis proteolytic activity may produce ragged amino termini, thereby
p:covidirg a possible e>q:>lanation for the varied ioolecul.ar weights arxi
microcharge heterogeneity often associate:l .with IL-1.

'Ihe human ctNA
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II.r-1 clone isolated by Aural an:1 Dinarello (13), denalstrated a'lly a

distant relatiooship with the :nardne IL-1 of Ianedioo an:1 Mizel (76).
Al.though the relatiooship of these IL-1 molecules may be distant,
there does exist a significant degree of sequence hcm:>logy an:1 struc-

tural similarities.

Both of these :reoanbinant cmAs have sham the

capability of producirg biologically active molecules dem::mstratin:J

their furx:tional relatiooship (167,303).

Protein sequence data irdi-

cate that these :reoanbinant forms of llllrine an:1 human IL-1 have amino
termini

beg~

at amino acid 115

am

117 respectively, gene:ratin:J

IL-1 with a molecular size of 17,300 whose forms also oorrelate in
terms of their

net charge for each species. Amino acid sequence of

the amino terminus

am ~

cleavage fragments of the pI 6. 8 species

of nonnal human IL-1 (36) conclusively shows that this species of
IL-1 is coded for by the human crNA isolated by Auron §t .sY,. (11).
'lherefore, it does appear that the IL-1 clones produced by Auron

am

Ianedioo oorresponi to forms of IL-1 c::ormonl.y desc::ribed in the literature.

'lhe absence of stron;J hcm:>logy between these molecules (11)

suggests a possible explanation for the lack of antibody cross

tivity in spite of functional s.iltlilarity
observed in bioassays (65,138).

in human

am

species Wepemence

Although antigenically distinct,

these m:>lecules still presumably retain a

cell activation.

am

:reac-

CXllUOOll

site required for T

'lhe c-tenninal amino acids between residues-150-186

161-197 in mrine IL-1 demonstrated the strcrgest regicm

of hcm:>logy irdicatirg this region as a key to the functional role in
IL-1 bioactivity.

statistical evaluation of protein (59) irdicates

these tw genes appear to be members of a nultigene family as q:p:>Sed
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to beinj species counterparts (11).

nrm.mex am syntax corporations
tial relationships.

Recent collaborative "WOrk by

has shed :nx:>re light on these poten-

'Ihey have obtained

am

sequenced two different

human cWA IIr-1 clones, whose gene products they have referred

IIrl ali;ila

am

IIrl beta (181).

Al.t:hcuj'l this IIr-1 nomenclature is

relatively new in the field, the al};ila
became widely accepted terminology.

characteristics of human IIr-1 ali;ila
clone, isolated by Auror1

am

to as

am beta designations

have

Table 2 briefly sunnnarizes the

am beta.

'!he human cWA IIr-1

Dinarello (13), was foun:i to be essen-

tially identical to the human IIr-1 beta produced by Immunex. Amino
acid sequence oarparison of the I..anedioo reccmbinant mrine IIr-1 with
human IIr-1 al};ila fran IllmJneX inlicates a close relationship between
these two proteins which share sixty-two percent amim acid hcm:>logy.

statistical analysis of sequence hanology inlicates Inm.mex's human
IIrl alP1a is the lll.lrine IL-1 oountexpart (12).

'!he first 39 N-ter-

minal amino acids sequenced fran an IL-l-like protein i;m-ified f:ran

ooncanavalin A (Con A) stimulated human ll0'10cyte supernatants,
a molecular 'Weight of

~tely

l 7, ooo, sb::Ms extensive hcm:>logy

to amino acids 117 to 155 of the cr:NA-derived
sequence (300).

least two genes

havinJ

human IIr-1 precursor

All this data stron:]ly suggests that there are at

c::odinJ for

IIr1.

'1hese forms of II.r1 appear

to be

distinct yet distantly related.
Considerinj the possibility of nul.tiple genes producin] IIr-1, a
major issue to be investigated in IIr-1 research is the rarxJe of
biological activity associated with each of these gene products.
Apparent differences in activity have been detected in the primary
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translation products of IL-1 aliiJa

am

IL-1 beta; with IL-1 aliiJa

de:nalstratin;J IL-1 activity, while umer similar ooniitioos, IL-1
beta does not (181) •

P.roducticn of large quantities of :recanbinant

fo:rn& of IL-1, alQ'XJ with the producticn of Da10Clcnal antibodies
specific for these different fonns, will allow the elucidation of the
biological activities associated with each groop.

Amino acid sequence analysis of IL-1 polypeptides has

all~

carparison of IL-1 to several other lynpioki.nes with no sequence
h.anologies seen with IL-2, IL-3, ganuna-interferon,

am granulocyte-

macrq:hage oolony stimulatin;J factor (11).
3.

sources am

Production of IL-1

Cells of the m::>noeyt:ejmacrq:haqe lineage were first thc:u;1ht to
be the sole

source of IL-1. M:>st tissue sources oontainin]

na'lO'-

nuclear piagocytes, includin;J peri:r;ileral blood m::>n0cytes (90,91) I
alveolar mac:cq;tlages (10,278), hepatic RUpffer's cells (66), splenic
macrq:hages (10), peritoneal macrqilages (136,216), bone marrow

Table 2.

craracteristics of human :recanbinant IL-1 aliiJa

craracteristic
Major secreted species by
stimulated ma~ge

PrimaJ:Y translaticn

IL-1 alliJa

am beta.

IL-1 beta

No

Yes

30,606

30,749

18,063

17,377

4.9 - 5.3

6.8 - 7.2

product MW (daltons)

Final cleavage product
MW (daltons)

!so-electric point (pI)

20

adherent cells (160), an:i placental lla'lOJ11Clear pmgocytes (87), have
been shatm

assays.

to produce IL-1 usirg either the emogenous pyrogen or IAF

'!he production of IL-1 has also been associated with myelo-

ioonocytic cell types, such as P388Dl, J774, U937 am 'IHPl (237).
other cell types of non-macrqbaqe lineage also produce IL-1

response to a wide variety of still'llli.

in

'1hese non-macrqilage cells

include epithelial cells of the skin, epidermal keratinocytes, (171,
172,173,264), arxi cornea (104), glia arxi gliana cells (88), glanerular mesarqial cells (169), girgival exudate cells (45), I.arqer.hans'

cells (64), lymphci>lastoid B cell lines (6), stimulated B cells
(267) / large granular l}'lllilocytes (IGL) (266) / fibrd>lasts (127) /
an:i, mst sw:prisirgly, polYJID:qilalllclear cells (FMNs) (218,318).
'!he strateqic location ard wide distribltion of IL-1 producirq cells

supports the ocn:::ept that this soluble mediator is clirectly involved
in host defense mechanisms ( 64) •

Initial sbxlies (158) Sl¥J9eSted that IL-1 was produced in rl.Y"Q
without still'lllation.

umer

study

erdotoxin,

However, it was fami that the macrqhages

wre still'lllated by picogram per milliliter levels of

wch

is bela.r.r the limit of detection by the limulus

lysate test, but often fourxi oontaminatirg laboratory materials (9).
Use of the cationic antibiotic polymyxin B easily rules rut contamination by negatively charged lipid A oontaini.rq erdotoxin JIDlecules
without inpairirg cell function (58,72,256).
'!he.re is a wide variety of agents capable of imucirg IL-1

production by llD1'l01'1Uclear };ilagocytes.

Jtt:ist of these agents are pyro-

genic, producirg fever in humans am experimental animals ( 69) • Aside
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fran gram-negative bacterial endotoxin, other microbes, microbial
fractions or microbial by-products such as gram-p:>sitive bacteria
(cell walls, mmmiyl dipeptide, exotoxins), yeast cell walls (zyno-

san), sp:irodletes (35) arxi viruses may also irXluce !Ir-1 production.
A 20

to 30 kd toxin produced by sta'Q:lylococcus aureus, isolated frau

patients with toxic shock symrane, has been shown to be equal in

potency to gram-negative eniotoxin in its ability to imuoe production of IIr-1 in vitro

am JD vivo

(126) •

Inflammato:ry agents such as

bile salts, etiocholanolone, urate or silica

(73), csa, arxi

c:i:ystals

antigen antibody oanplexes fonoed in antigenic excess, also irXluce
IIr-1 production

JD vitro (74). Various plant lectins,

hemagglutinin (mA)

am con A

(22,241),

am antigens

such as Iityto-

(44) includin;J

alloantigens (63), irduce !Ir-1 stimulation via lynphaki.nes.

Macro-

phages activated with colony stimulatin;J factors have also been shown

to respord by increasin;J !Ir-1 production (213).
It is generally thought that surface receptors are involved in
the stimulation of };ilagocytes to prcxiuce !Ir-1 (78) •

It bec:aoos

apparent that stimulation 1Illst occur at the macrqilage membrane since

blocld.rq of phagocytic uptake of spirochetes (35) or urate crystals
(73) by cytochalasin B or colchicine does r¥Jt inhibit IIr-1 stiirlllation.

serum am

oanplement ccup:nmts are also thought to play a

role in the eventual production of !Ir-1 by activated macrqilages.
Although r¥Jt required, serum enhances the sti.nulation of IIr-1 production in vitro by erdotaxin arxi staii}yloooccus midermidis (154).
'!be p:>sSible relationship of serum enhaix::ed !Ir-1 production may be

explained by recent firxlin';1s that macrqilages have receptors for the
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anaphylatoxin,

esa will

csa,

on their surface (46), arxi that pn-ified human

imuce macrqilage IL-1 production (99).

'lhe Ia (I region-

associated) or HIA-I:R (human leukocyte antigen DR) glycoproteins on
the surfaces of macrophages have also been inplicated in the activ-

ation process leadin;J to IL-1 prcx:luction.

'1hese surface markers,

believed to participate in antigen activation of T cells which bear
receptors for Ia (260,297), may perfo:nn a receptor-like role on the
surface of macrophages.

Several reports have deloonstrated that T

cells imuce IL-1 :release fran macrophages via an Ia-:restricted
interaction (76) arxi that anti-Ia mnocla1al. antibodies inhibited
both T cell arxi I.PS imlCed IL-1 production (77 ,96).

Incubation of

mnonucl.ear pmgocytes in nonstinulatirg culture ocnlitions for 24-48
boors results in the loss of Ia surface markers oo these cells.

Associated with this loss of Ia surface antigens is the ability to
:fun:::tion as aooessoey cells for antigen processin;J arXl produce IL-1

in response to I.PS (54) • Treatment of these cultured cells with

i.rnanethacin prevents the loss of both Ia expression arxi IL-1 producin; capability (284).
receives stimuli

'1hese observations stron;ly suggest that Ia

culmina~

in the release of IL-1.

It should be noted that not all macrqilage stimulators in:iuce
IL-1 production.

Isvamisole, tuftsin, arxi Naio4 , which perturt> cell

membranes, cause superoxide aniai generation arxi activate other known

macrophage furx:tions, do not stimulate IL-1 production by human
macrophages (154) • A smprisin;J result of amino acid analyses of
reccmbinant IL-1 is the lack of a classic signal peptide (13,167,181)
which directs newly synthesized proteins to their ultimate destin-
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ation, whether in or out of the cell (26).

'Ihis result leaves open

the lorg-st:ardin;J questicn of how IL-1 is excreted fran the macro~am other

cell types.

'lhe fin:linJ of a slightly hyarc:plabic

region of seventeen residues at the amino terminus of both llllrine
(167) am human (13) IL-1 may represent a functicmal. danain involved
in transport (11), altha.lgh this region bears little resemblazx::e to
signal sequences foun:l in other secreted proteins leadin:j to the
previously described inefficient secretion of the protein (91) •
Dinarello has postulated that the suicidal nature of macrq;ilages
involved in their fight against infection may lead to the release of
IL-1 (182) •

'Ihis type of mass release may be inportant in the

infla:nunato:cy process ( 64) • other investigators have identified
surface membrane associated IL-1 with potent thyioocyt:e am T cell
stillW.ato:cy activity on demritic cells (217), fixed macrq;ilage mnolaye:rs, am an membranes isolated fran unfixed macrq;ilages (151).
Membrane IL-1 appears to be an integrated membrane protein since it
was solubilized by detergent, but not eluted by (Ethylenedinitrilo)-

tetraacetic acid (EDI'A), high salt, or 10"1 l=fl treatment of the membranes.

'Ihis report Wicates that previous "Werk dena1Stratin] IL-1

imepen:ient T cell lines (21) are not imepenient of IL-1, but rather

that fixed macrqi1ages have sufficient IL-1 en their surfaces to sup-

port T cell proliferation withalt the adlitian of soluble IL-1.

'lhe

authors suggest that iniucticn of membrane IL-1 may focus the activation signal to T cells biJXlirg to the macrqilage via their antigen
receptors (151).

'Ihis 'WQJld obviously all0"1 for the enharx::ement of

the inm.me response wit:hoot the necessity of mass mac:rqi'lage lysis.
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4.

Inununologic Activity of IL-1
'lhe ability of cells

to

reswm to IL-1 ai;:pears to work via

specific membrane receptors similar to that described for other horIIVJileS

(71).

Workers at Illl1amex have shown that human 125I-IL-l bi.ms

specifically to cells of lyJ!liloid or fibroblast/epithelial origin;
cells on which IL-1 is kIXMll to have a biological effect (71).
was fooni

IL-1

to bil'Xi with high affinity, am to associate with a mem-

brane protein of 80, ooo 100lecular weight, suggestirq a specific membrane bourd receptor for the protein.

'!here are a wide variety of inm.mologic actialS DKXiulated by

IL-1 which may be shown to be inport::ant in tunDr i.nm.mity.

'!he abil-

ity of IL-1 to be mitogenic for t.h.yD:>cytes (89) was the earliest
recognized effect of IL-1 on the inm.me system.
reference assay for IL-1.

It remains as the

'lhe ilrportanoe of this lynphokine in T

cell activation is demnstrated by the ability of IL-1 to restore
antigen or mitogen .in:iuced T cell activation when antigen presentin:J
cells are reiooved fran the culture pop.llation by P"iysical means (281)
or by use of anti-Ia treatment (76,159), SU39estin; that IL-1 is a
required CCl'lp)Ilellt leadinJ to expansion of T cell pc:p.1latiais.

IL-1

has been shown to sti.Jllll.ate the production of interleukin 2 (IL-2) in

both murine am human systems (178,254).

'lhus, it has been prcposed

that IL-1 stinulates antigen or lectin activated T cells
cells in the Go

cycle,

rest~

result~

allc:M~ the

state to enter the G1 stage of the cell

in the release of IIr-2 by these cells (159,281).

Antigen activated T

l~ bear~

.in:iuced by IL-2 to enter the S

P1ase of

IL-2 receptors are in tum
the cell cycle (53) •

In
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several reports it has been shalln that adjuvant active peptidoglycans
can in:luce IIr-1 productiai by lll.lrine arxi human naxmuclear cells
(128,242,299,310).

IIr-1 has deloonstrated similar imm.moenhaooirg

activity for defined antigenic systems

in

vivo, suggestirq that IIr-1

may be a oc:rnnv:>n m:xie of actiai of immunological adjuvants (285,312).
'lhe ability of IIr-1 to up-regulate the immune :response is mre clear-

ly seen by

INt antigen

in

cells (78) •

'lhe

analysis of T cells (31, 38) :re-

IIr-1 ~ to prarote the generation of

spordin;J to IIr-1.
helper cells

~ic

vitro arxi inhibit the generation of

INt l+

INt 2+ suppressor

INt 1+ T helper cells secret IIr-2 in response to

IIr-1 (140), augmentirg the generation of cytotoxic T cells (84,276,
301).

Antilxxlies directed against helper T cells which blook IIr-1

:flmction, prevent the production of IIr-2 by helper T cells, but also
prevent the generation of cytotoxic T cells, strorgly suggestirg that
IIr-1 stin'All.ation of cytotoxic T cells awears to :flmction via its
ability to imuoe IIr-2 (193).

'lhe conversion of the macrqilage de-

rived maturational signal, IIr-1, into a secxn:lary T cell derived proliferative signal, IIr-2, results in the anplificatiai of an antigen
specific immune response.

Aoother soluble macrqilage factor, ini-

tially described as BAF, was shown to increase levels of antibody to
sheep red blood cells released fran splenocytes of nude mice (309,

311) •

'Ibis factor was later identified as IIr-1 when it co-purified

with IAF (308) , arxi its activities were inhibited with antil:xxiles
against IIr-1 ( 166) •

continued reseal:dl has shown that B cells are

reactive to IIr-1 durirg at least two stages in their develcpnent.
Farly stage B cell maturational control was initially reported by
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Hoffmann et al. , (118) who described a macrophage factor irrlucin;J
maturation in pre-B cells.

'Ihis factor was verified as IL-1 when

:p.Irified IL-1 st.llrulated ka:rpa light-chain production and subsequent
expression of membrane immunoglcbll.in (Ig) in pre-B cells (97).
has also been shown

IL-1

to synergize with suboptimal c::a"Dll1trations of

anti-ni chain, .llxlucin;J B cell pmliferaticn and terminal. differ:entiatioo (82) •
this

in~

'!be capacity of antibodies against IL-1 to abrogate

antibody synthesis (166) I straqly Wicates that IJrl

may be critical for B oell activatioo
IL-1 activation appears

l~

to antibody production.

to be required xelatively early (within

twenty-four hours) after B oell stinulation by antigen or antiimmunoglab.llin (117) as are other early actin;J cytakines such as B
cell growth factor (aa;F) (124) and possibly IL-2 (161)
cells thra1gh mitosis.

~ch

drive B

Followin;J early B oell activatioo, late

actin;J lYJlPlo]dnes such as ganmia-int.erferon (277 ,320) lead to further
B cell differentiation and production of antibody.

'1he source of

IL-1 needed for B oell activation and differentiation was

be the activated macrophage.

HoWeve.r,

assunm to

recent in vitro sbnies inli-

cate that B cells may play the role of accessoey cells (8,47,191) in
the absence of ma.crqilages.

'1he absence of I~l-like activity in B

cell culture super.natants produced an apparent paradox sin=e there
appeared to be no souroe of IL-1 available to T cells in these systeins.

'!he fi.rxlin;J of surface membrane IL-1 on ma.crqilages (151)

leads to the resolve of this prci:>lem when the same investigators
determined that B cells could be irxluoed to express membrane IL-1

only when st.llrulated with both anti-immunoglab.llin and T oell lyq:ho-
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kines (152) •

In

contrast to B cells, macrqilage exp:ression of IL-1

is not deperrlent on T cells or their products ( 151) •

'lhe

awearanoe

of an IL-1 inhibitor, produced by an Epstein-Barr virus-transformed
hUman B cell line (267), may acxnmt for lack of IL-1 activity in B

cell supernatants (6,267)
between accessory B cells

am
am

the necessity of cell to cell contact
responiln:J T cells.

'lhe differences in

the stimuli needed to irxiuce membrane IL-1 on the surfaces of B cells

ard macrqilages suggests that these antigen presentinq cells may

serve diverse roles in the i.rduction
response (152) •

am maintenance

of the inm.me

Also, the apparent lack of a signal peptide in the

precursor fonns of reoanbinant IL-1 isolated to date suggests that
the membrane form of IL-1 may be derived fran a different family of
genes than those associated with the soluble form of IL-1.

Another cell in the inm.me system which responjs to IL-1 is the

IL-1 is a chem::>a.ttractant for these cells (170,265), it

macrqilage.

in:iuces the release of prcstaglardin E2

(~)

in activation for tunm'-oell killinq (240) •

(68) , ard is involved

Prostaglardins have been

inplicated to have inhibitory effects ai macrq:ilage productiai of
IL-1 (78).

Whether this is a case of autoregul.atiai with the same

macrqi1age cell producirq IL-1 responiln:J to its release by producinq

am
5.

releasin;J

~has yet

to be determined.

other Biologic Activities of IL-1
'lhe ability of a host derived soluble proteinaceous factor to

irxiuce fwer associated with m:>st, if not all, pyrogenic substances
(6,69) initiated :researdl into EP.

'Ibis protein appears to regulate

body tenperature by raisin;J the hypothalmic setpoint as a function of
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EP's ability to increase levels of prostaglamins in the brain arxi

oerebra1 spinal fluid (23,50).

As the methodology of protein chem-

ists inproved allowirq the separatiai arxi examinatiai of partially
purified factors which augment a variety of p:iysiologic responses
includirq fever arxi the acut:e-pmse response, it becaJie apparent that
these biological activities

'lim'e

biochemically inseparable (131).

'lhe fi.rxiin; that EP arxi IAF activities were also biochemically

inseparable in several different animal species (216, 261) , catalyzed
the developnent a broad oorrept li.nkirg the host febrile response to

inm.moregulatiai.
It has :been well established .that the acute response to infectious diseases arxi pyrogenic substmxles prcxiuoes neutJ:q:bilia in
associatiai with fever (56).

'!he neutrqililic response generated by

IL-1 seems due to the accelerated release of mature neut:rophils from

the bone marrow reserves, as there is a severe loss of mature neutro-

phils in the marrow followirq injection with EP (134).

IL-1 has also

:been observed to dramatically increase the synthesis of acute phase

reactants, a group of proteins produced by the liver in response to
infectiai or inflammatiai {196,287).

'!hose acute phase :reactants

normally present in the plasma; sudl as serum amyloid A (187), fibrinogen (133), haptoglabin (120,133), arxi ceruloplasmin; generally
increase several fold when the host is stinul.ated with IL-1. . '!hose

proteins normally seen in the plasma at extremely low concentrations,
such as c-:reactive protein, rise several hurxh'ed fold in response to
IL-1 (195,293).

Whether IL-1 is actirq alone or together with other

factors in the iniuctiai of these acute phase :reactants is still tm-
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clear (64) • 'lhe accelerated synthesis of ceruloplasmin by IL-1 (131)

acoamts for the increase in the plasma level of oog>er ions, generally considered vital to oanbat bacterial diseases (251) •

TlNo other

plasma divalent cations (ziro am irm), affected by the presence of
IL-1, show a rapid drcp in plasma concentration (132).

IL-1 imuced

neut.rqnil. degramll.ation leadin;J to the release of lactoferrin (144)
leads to the rapid drcp in irm levels am is a major host defence
mechanism against microbial infection.

IL-1 has also been ilrplicated

in the regulation of tissue catabolism durirq infection or trauma
when the host must Dd:>ilize a variety of oc:qx>nents needed for syn-

thesis or energy by irducirq nuscle tissue proteolysis (14,49), bone

resoi:ption by osteoclasts ( 102) , an:l cartilage breakdown associated
with oollagenase am proteoglycanase production by human chomrocytes
(103).

6.

Potential Antituioor Activities of Interleukin 1
'!he many biologic activities of IL-1 diSOJSsed above, both in

the nature of inm.moregulation an:l piysiologic regulation, demon-

strate the potential use:fUlness of this 1la10kine as an in vivo therapeutic agent.

'!he activated macrqilaqe is

t:houJht to play an inport-

ant role in host defense against malignant neoplasia by exertin;J a
cytotoxic effect an tunm' cells (85) •

IL-1 has been shown to prcm:>te

human llalOcyte-mediated tunm' cytotoxicity possibly by prolon;Jirq the
cytotoxic state of :ironocytes (235) • Macrq:hage cytotoxic effects are
thought to be mediated by several possible effector ioolecules includ-

irq lysosanal

enzymes (116),

oxygen intennediates (221), arginase

(55), a neutral p:roteinase (2), an:l tuioor necrosis factor (180,319).
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Purification of human IL-1 (185) has allowe:i Onozaki et al. to de.nal-

strate the direct cytocidal am growth inhibitory capability of IIr-1
against a human melanana oell line

ID Yi1;;rQ (236).

'lhus aail.n:] IIr-1

to the list of potential macrophage cytotoxic mediators.

Human

JOC>l'lO-

cyte derive:l IIr-1 has been shown to augment the activity of highly
p.irified human IGL or NK cells which are cytotoxic to a variety of
malignant cells (141,225) am have been inplicated as inp:>rtant mediators in the prevention of tuJoor development am metastasis (110,
137).

Augmentation of this activity inplies a possible role for IL-1

in inm.me surveillance of spcmtaneaJs or metastatic tuJoors (186).
'Ihe previously discussed ability of IIr-1 to augment the inm.me

re-

'-·

sponse to specific antigens

ID vivo (285,312) allaws speculation that

IIr-1 may be able to save an immunoadjuvant for tun¥:>r associated

antigens.

Several inp:>rtant observations can

ments discussed in this revie'ft'.

rt:N

be made f:ran ele-

First, it lNOUl.d appear that C.

parvum may act as an immunoadjuvant in the C57Bl/6:EI.r-4 tun¥:>r lOOdel
by

enhancin:J

macrophage fuootion.

5ecorxlly, the m:xlulatory ftuttions

of IL-1 have been shown to nv:>st likely act via lyqhocytic pcp.ilations.

'Iherefore, by

oanbinin:J

the protective

c.

parvum therapy with

systemic IL-1 administration, this study set out to detennine if IL-1
could IOOdulate a protective iimnune response to the nonimmunogenic
EL-4 lymphana.

'Ihe effects IIr-1 may have on the involved lyn'Plocytic

populations will allOW' suggestions as to possible ne::-.hanisms which
might lead to the development of b.uoor immunity in this system.

CliAPl'ER III

A.

'!he Mice
CS7Bl/6 female mice, ages seven to twelve weeks cbtained fran

Jackson Iaborato:cy, Bar Harbor, ME, were used for all IL-1 in vivo
tum:>r protection studies.

Similarly sexed arxl aged C57Bl/6 mice

obtained fran Olarles River

Breedin.1 Iaboratories,

Inc., Boston, MA,

arxl Iab SUR;>ly, Plainfield, IN, were utilized for macrqilage activa-

tion studies.

Lynploid tissues fran DBA,12J arxl CJ:fVHeJ mice, aged

seven to sixteen weeks (Jackson Iaboratory), were used for IL-1

assessments.
B.

'!he Bacteria
'!he Coeynebacteritnn parvum strain 4182 (Propionibacteritnn

acnes) was been obtained fran the Pasteur Institute, Paris, France,

arxl periodically identified by API 20 Anaerobic System (Analytab

Products, Plainview, NY) (212,283) arxl metabolic em-products determination by gas-liquid chranatograpiy (214).

'!he bacteria were grown

anaerobically in liquid culture usirg Brewer's thioglycolate neiltnn
with inlicator (Difeo Iaboratories, Detroit, MI).

Ten milliliter

starter cultures were incubated at 370c for five days, then transferred to one liter thioglycolate broth cultures.

'!he cultures

remained at 370c for seven days urxier anaerobic corxlitions with
occasional agitation.

'!he organisms were haJ:vested with the Beckman

TJ-6R centrifuge (Beckman Instruments, Inc., Palo Alto, CA) at 1500 x
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gravity (g) for twenty mimtes,

am washed

five times with sterile

'lhe organisms were heat-killed at sooC for thirty minutes

saline.

with inspissation, aliquoted at 2 x 109 cells per ml am stored at
-2ooC until needed.

c.

'lhe Turoc>r Cell Lines

'lhe EI.r-4 lynphana, a 7,12 diamethylbenz(a)-ant.hraoene in:luoed

turoor, was originated in 1945 by Gorer fran C57Bl/6 mice.

'lhe Eir-4

lynphana has been shown to be a tumr of lCM illm.nx>genicity (39,100),
am nonsusoeptible to NK lysis (114).

'Ibis tumr was C'btained fl:an

Dr. R. Hetioennan, Iaboratory of Inm.modiagncsis, Naticntl

Institute, Bethesda,

Qm:ler

MD.

'lhe RBL-5 lynphana, also obtained fl:an Dr. Hel::beman, is a

Rausher mrine virus-irxi11Ced lynphana (189),

geneic in the C57Bl/6

am

like Eir-4, is

syn-

DD.JSe.

'lhe YAC-1 lyqtiana is a Molooey mrine virus-irxi11Ced lynphana

(280) which has been shown to be susceptible to NK lysis (114,141).
'lhe EI.r-4 ascites bmm" banks were maintained

passage.

.in YiYQ

by I i. P• I

A 0.1 ml suspension of EI.r-4 ascites cells in Hank's bal-

anced salt solution (HOOS) at 1 x 107 cells/ml was injected, i.p.,

into syn;ie.neic C57Bl/6 mice, typically at ten day intervals.
RBL-5,

am

YAC-1 cell lines were maintained in

~ by

EI.r-4,

grcM:l1 in

suspension cultures in RIMI-1640 culture medimn (Grani Islarxi. Biological C'alpany, Gram Islam, NY) (GIBCX:>) , Iii 1 .1 to 1. 3, suwlemented with five or ten pel'Oel'lt fetal bovine serum
activated at 56oC for

ale

(~)

(heat in-

hour) (GIBCX:>) 100 units/ml potassimn peni-

cillin G, 100 ug/m1 streptanycin (sulfate), 2.5 ug/m1 fun:}izone
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(Whittaker M. A. Bioproducts, wal.kersville, MD) arxi 2 JIM L-glutamine
(Whittaker M. A. Bioproducts).

All

.in vitro

cell cultures utilized

for experimentation or propagation in this study were maintained at
370c with five percent

a:>-i

in high humidity, unless otherwise state;i.

Media supplemented with L-glutamine arxi the antibiotics listed above
will be :referred to as oarplete medium.

All routinely in vitro

passaged cell lines were incubate;i in either 50 ml or 500 ml tissue
culture flasks (COmin;J Glass Works, comin;J, NY).

'!he P388Dl maaqi1age-like cell line, A'n::C-TIB-63, (American
Type CUl.ture COllection, 'l\Jm:>r Ilmmmology Bank, Rockville, MD) was

derived fran a methylc:holanthrene-imuced lYJlPioid neoplasm (P388) of
a DBA/2

m:iuse

(57).

It has been utilized consistently as a source of

erxiotoxin iniuced ImJrine IL-1 (155,205).

'!his cell line has been

shCMil to retain many maaqi1aqe cell-like properties includirq the

ability to

~gocytize

latex particles arxi

zyioosan,

firmly adhere to

glass arxi latex, arxi carry cell bourrl receptors for immunoqlcbllin
(Fe) arxi catplement (C3 ) (146).

'!his cell line has no detectable

surface inum.moqlcbllin (146) , exhibits high effector activity in an

antibody-deperxient cell mediate cytot:a>d.C system (252) I arxi synthesizes lysozyme (253).

'!his cell line was maintained

.in~

as mno-

layer cultures in oarplete RFMI-1640 mdium supplanented with ten
percent FaS.

A secorXl P388Dl cell line, obtained fran Dr. Y. _Yama-

mura (Ponce SC.hool of Medicine, Ponce, Puerto Rioo) , was a clam
cell line which oonstitutively produces IL-1 (317).

was derived by Dr. Yamanu.Jra
(D.lke University Medical

'!his cell line

fran a cell line isolate;i by Dr. H. Koren

center, Dlrtlam, NC).

'!his cell line was
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maintained in vitro in catpl.ete m-alJila medium without rucleosides
(Grard Islarx:i Biological Catpany, Grarx:i Islarx:i, NY) supplemented with

seven percent FBS.

To avoid OCllfusion, the cell lines d:Jtained fran

the American Type CUlture a:>llecticn (A'ICC) arx:i Dr. Y. Yammmira will
be referred

to as P388DlA arx:i P388DlY respectively.

D.

Production

IL-1

by P388Dl Macrqibage cell Lines

IL-1 required for in vivo experimentation was produced usirq

the constitutive IL-1

generatin:J PJSSDlY cell line as previously

PJSSDlY adherent cells were nm:wed frail statiaw:y

described (317).

DalOlayer cultures with a rubber policeman or by rigorous pipett.irg.
'!he cells were pelleted by oentrifugatioo at 400 x q for seven

to ten

mimtes, washed once in HSSS, ani then seeded in 50 ml tissue culture
flasks at 2 x

io5

cells/ml in 10 ml of oarpleta m-al.Jila medium with-

out nucleosides plus five percent emotoxin-free FBS (HyClone IaOOratories

:m::. ,

I.ogan, ur) •

After three to five days of incubation,

the culture supernatants were harvested by decantation, then centri-

fuged an:vor filter sterilized by passaqe through a 0.45 um SWinnex
filter unit (Millipore Q)l:p., Bedford, MA) to renxJVe aey remainin;;J
cells.

'!be IL-1

oontaini.n;1 ocnlitioned medium

was aliquoted

frozen at -200c tmtil required for experimentation or assay.

am
IL-1

has been shc7tln to remain stable for at least six lOOllt:hs umer these

c:x:>niitions (205).

P388DlA cells utilized. for product.ion of IL-l were prepared
for seedinq in the same manner as described for the PJSSDlY cells.
Production cultures were seeded at 2 x 105 cellsjmljwell in 24-well

tissue culture plates (Falcon Plastics, Ios

~eles,

CA) •

eel.ls were
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incubated either with or without 10 uq/m1 lipopolysaocharide (LPS) B
frail sal.npnella tygiosa 0901, (Difeo, Detroit, MI) for three days.

'!he c:W.ture supernatants were harvested, aliquoted, ard stored as

described above for P388DlY supernatants.

caxlitioned supernatants

fran macrqilage c:W.tures not qiven LPS were utilized in the in vivo
protection experiments as control macrqi'laqe comi.tioned mcUa.

Recombinant

E.

II.r-1

Purified recanbinant murine IL-1, derived fran a cloned murine
cmA qene for IL-1 in F.scherichia coli (167),

was generously supplied

by Peter T. I.anedioo (Hoff'mann-IaRoc:he In::. , Nutley, NJ) •

paration of IL-1 had an activity of 4 x 106 units/ml

'!his pre-

am was main-

tained in SM Guanidine hyOroc::hloric acid (HCl) buffer.

'!he recanbi-

nant IL-1 sanple was diluted to the concentration desired for assayi.rg or for in vivo experimentation in HBSS containin;J 250ng/ml. human
serum albumin (HSA) as a carrier protein.

aliquoted

am

'1he

stored at -2oOc until needed.

diluted IL-1 was then

similarly prepared HSA

sol.utia1S (250ng/ml) withcut IIrl were aliquoted

am

stored at -200c

used as control injectiai mixtures for the nurine recanbinant

IL-1
F.

am

.in vivo protection experiments.
llr-1 Assays

'!he starxiard co-mitogenic thyioocyte assay was utilized to

assess llr-1 activity as previoosly described by Mizel (209) • _'!he
thynDJS from either a C3JVHeJ or DBA/2J

JOC1USe

followin] cervical dislocation of the animal.

was aseptically :ren¥JVed

A si.rgle cell suspen-

sion was prepared by passaqe of the tissue thrcu3h a 60-mesh wire
screen into HBSS.

'!he suspension was decanted into a 15 ml conical
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centrifuge tube (COmin;J Glass Works I comin;J I NY) where large cell
cl'UllpS were allowed to settle for five minutes before the cell suspension was again carefully decanted to another tube.
washed

'Iha cells were

once in HBSS, resuspeMed to l x 107 cells/ml in oaiplete

RIMI-1640 medium,

am

plated at 100 uljwell in 96-mi.crowell. tissue

culture plates (Microtest III, Falcon Plastics, IDS ArYJe].es, CA).

'!he culture medium was supplanent:ed with FBS, piyt:dlemagglutinin P

(mA-P) (Difeo, Detroit, MI),

am

2 mercaptoethanol (2-ME) (Sigma

Cllemical co., st. I.alls, H:>); such that a final ocaoentration of ten

percent FBS,

o. 01

percent mA-P

am 5 x io-5

final volumes were added to each well.

M 2-ME was attained when

Varyin;J am::mits of test sam-

ples, rangin;J fran O ul to 50 ul, were added to each well with an
awropriate ano.mt of culture medium added brinqinq each well to a
200 ul total volume.

cate.

All sanples ard controls were tested in tripli-

Follc::Min;J sixty-six hours of

were PJ].sed with l uCi

3a-thymidine

incubation, the microcultures
(7. 6 Ci/ltm:>le) , l nCi in 20 ml

HBSS (ICN Bianedicals, Inc., Irvine, CA).

After an additional six

hours of incubatial, the microcultures were harvested onto glass

fiber filters (cambria;Je Techoology, Inc., cambridge, MA) usin;J a PHO

autanated cell harvester (cani>ridge Technology Inc.) •

'!he degree of

radiolabel inco:i:poration for each sanple was deter.mined usinq liquid
scintillation

~

{Unilux II, Nuclear-aiicago, I;les-

Plains, IL; or IS580l, Bedmlan Instruments, Irvine, CA).
A variatioo of the stamard IIrl assay described by Yamamura

(317) , utilizinj murine splenocytes, was also incorporated into the
study.

Splenocyte cell suspensions were obtained fran IB\/2.1 mice in

37
a similar manner as described aba\Te for the thyioocyte assay.

Eryth-

rocytes in the spleen cell suspension were destroye:i by rapid hypo-

tonic lysis with distilled water.

'lhe rema:i.nirg white blood cells

were washed twice with HBSS, and resusperxied in c:xmplete m-alpha
medil.ml supplemented with 0.01 percent mA-P.
included in the incubation mdia.

No FBS or 2-ME

For this assay cells

were

were resus-

penied to 2 x 106 cells/ml before platirx] 100 uljwell of the splenocyte suspension into inlividual wells of a 96-microwel.l plate.

Test

sall'ples and medil.ml were added to the wells as in the thyioocyte assay.
'Ihese microcultures iooubated for forty-eight hours followed by a
twenty-four hour p.ilse with 3a-thymidine.

Harvesting and radiolabel

countirg procedures for the splenocyte assay were the same as those
described for the thyioocyte assay.
Units of IL-1 were aJ:bitrarily determined by equatirx]

aie

with the capability of stilmJlatirX] thyn¥:>Cytes or splenocytes to

unit

aie-

half the maximal value obtained in the assay with a high activity
P388DlY supernatant :refere?D! lot of IL-1.

G.

In Vivo 'l'Ullm'

Protectial smiles

CS7Bl/6 mice were chal.len;Jed intradennally (i.d.) on the right
flank with a 0.1 ml suspension of EI.r-4 t.uioor cells susperded in HBSS.
'Ihe tull¥)r dose rarqed fran 1 x 103 to 5 x 103 cells per injection.
'Ihe EI.r-4 ascites cells had been previously rerooved fran the periton-

eal cavity of a m.:irine tull¥)r bank, washed once in HBSS, and prarptly

injected in the mice either
heat-killed

c.

alaie

or as an admixture with 2 x 109

paryum bacterial cells.

'Ihe

c.

parvum suspension had

been lightly sonicated after :rem:wal fran freezer storage to elf.mi-
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nate bacterial clunpirq before admixture with the tmoor cells.

As

previously described (121) , animals receivirq both tmoor challen;ie
protocols were divided into two groups.
was given m further treatment.

one groop fran each protocol

'1he secxni groop of animals fran

each protocol was given aoxmpanyirq systemic IL-1 therapy.

Animals

reoeivirq IL-1 therapy (either IL-1 cxmt:ainin;J oon:li.ticmed culture
supernatants obtained fran the P38801Y CXllStitutive IL-1 produc::irq
cell line, llB.lrine :recanbi.nant II.r-1 or U>S irrluced P388DlA cell line

oorditioned culture supernatants) were administered equal unit dosages of IL-1, i.p., everyday or
day of tUloor challen:ie

ai

alteJ:.nate days startirq with the

am eniirq nine

days later.

cantrol animals

received aooanpanyirq systemic therapy (in the fom of either P388DlA

oon:li.tioned culture supernatants or a 250 ng/ml. HSA solution) usirq a
c:x:arparable injectioo protocol. A total of 100 units of IL-1 was
administered to each

DDJSe

reoeivirq this therapy.

ically checked for survival.
challen:ie

am

Mice were period-

All mice survivirq this initial tUloor

showirq oo visible signs of tum::>r growth after thirty-

five to fifty days were rechallen:JEd with the EL-4 tUloor.

'!he re-

challen:ie ioocul.um was injected i.d. on the right flank between the
site of the initial tUloor c:hallen:ie am drainin;J axillary lyirq;t>.
nodes.

'Ihe Eir4 tUloor dose was equal to that given for the initial

challen:ie am

00

further therapy was administered to these animals.

Mice were evaluated periodically for survival.

In separate experi-

ments, mice were rarxianly selected at successive time periods followirq either initial or secorx3azy Eir4 challen;ie for .in vitro evaluation of lYll'Ploid immunological. responsiveness.
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H.

Radiolabelim 'l\mpr Target Ce1ls
Either in yitl;:Q passaged EL-4, :RBI.r-5, YAC-1, IG62, or in vivo

passaged EL-4 ascites tullDr tal:get cells were washed once after har-

vestin], resusperDed in HasS ani counted.
3 x 106

am 1 x 107

tullDr cells

A suspension of between

was pelleted by centrifu:lation at

400 x g for seven to ten minutes.

'!he supematant

was discarded ard

the cell pellet resuspenjed in the residual HESS (150 ul). 'l\noor

target cells were radiolabeled by incubation with 100 uci to 200 UCi
Na2 51cro4 ( 51cr) (New Erqlard Nuclear, Boston, MA, or Amersham Co:cp-

oration, Arlirqtan Heights, IL) for forty to sixty minutes with
freqUent agitation.

'lhe

SJ.er

labeled cells were pelleted, washed

four times in HasS, ani resuspemed in oatplete medium for immediate
addition to effector cells at 1 x 104 taI'get cells per well.

I.

T Cell Mediated <rYtotoxicity
T cell-mediated, tullDr cell cytotoxic activity of ly.q:hoid

tissues taken fran tullDr
foll~

chall~

antitullDr therapy,

animals at varioos time points

was assessed follO!rlin;J pr<XJedures des-

cribed by Brunner ani colleagues (34).
cervical dislocation.

Mice were sacrificed by

'lhe spleen ani lynph nod.es drainirq the site

of the tullDr dlal.19n39 were aseptically reiooved fran each animal,
passed through a 6()-gau:Je wire mesh to obtain a cell suspension, arxi
washed once in

:aass.

Eryt:h:rocytes in the splenic suspension were

destroyed by rapid hypatanic lysis with distilled water, followed by
several HESS washes.

Splenic am lynph node effector cells were then

resuspenjed in oatplete RPMI-1640 medium with ten percent FBS.

Cytotoxic activity of all cell pc:p.1lations were dete.nni.ned at four
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effector-to-target (E/T) ratios by serial diluticn of effector cell
ooncentratia'lS, rarqinJ fJ:an 1 x io6 to 1.2 x 105 cells per well, in
rourrl bottan chambers of 96-well tissue culture plates (Fal.c:ai Plas~

tics) •

rme effector

cells were evaluated at the highest pos-

sible cell concentraticn allowin,;J for foor serially diluted E/T

'lhis variability was due to the low number of cells occas-

ratios.

ionally obtained fJ:an these tissues.

All E/T ratios ard oontrols

were performed in triplicate (1 x io4 5J.cr labeled tumr target cells
were added to each well in 100 ul of medium) •

brought to 200 ul with media when necessa:ey.

Total well volume was

'!he cytotoxicity

cultures were qently pelleted by centrifugation at 100 x q for five
minutes.

Followin;J a fCAJr-halr incubation period, the cultures were

pelleted by centrifugaticn at 400 x q for five minutes.

R.adiolabeled

tumr target cells incubated witha.tt effector cells were used to

detennine the spont.aneoJs cellular 5J.cr release.

Maxilmlm cellular

release was obtained by lysinJ labeled tumr targets with Nonidet P40 (NP-40) (Sigma Chemical

co., st.

Louis, K>).

Released radiolabel

was harvested by renovirq 130 ul of supematant fran each 'Well,

am

counted on a Beckman Gamma 4000 gamma radiation oounter (Beckman

Instruments, Ioo. , Irvine, CA) with data expressed as CX>1.ll'lts per
minute (CEM) •

Results were expressed for each E/T ratio as percent

specific release (PSR):
PSR = 100 x

CCEM in experimental well) - CaM in control well>
(aM in NP-40 well) - (aM in control well)

PSR data were represented grapiically as a furttion of culture dilution.

Linear least square curve fittin;J usirq cmve

Fitter-~

soft-
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ware (Interactive M:i.crCMare,

:rrx:. ,

Imlblny, er) determined the best

straight line though the PSR data points.

Usin;J this analysis the

slope of the line will vary deperxtinJ on the prqx>rtion of cytolytic
cells and the efficiency of cytolysis in the effector pc:ptlation
(290) •

Results, extrapolated fran the fitted curve, are expressed as

lytic units (L.U.) per cell culture ' with one L.U. defined as the

inverse of the fraction of a 1 x 106 effector cell culture require:l

to achieve ten percent specific release (43).
J.

Natura! Killer cell Activity
'!he NK assay was performed in the same manner as that des-

cribed above for the cytotoxic T cell assay, except that the (51cr)
radiolabeled target cell was the NK susceptible YAC-1 tum::>r cell
line.

Since NK activity is seen in uninm.mized animals, the deter-

mination of aey n¥:Xiulatiai of this parameter 1l'llSt be measured carefully against the control protocol mice.

As di SOJSsed in the pre-

vious section, data are graprl.cally expressed as PSR, then cx:nverted

to L.U. of activity.

statistical evaluation of the data was deter-

mined by t-test analysis of the PSR for the 100 to 1 E/T ratio data

points.
K.

Macrophage 'l\nooricidal Activation and Assessment

1.

'Ihe 'lhioglyoolate Irxiuoer
Brewer's thioglycolate broth (Difeo, Detroit, MI), used_ for,

i. p. , injection of mice, was prepared as described by canpbell, §t
al. (35).

An autoclaved 100 ml aliquot of thioglycolate medium was

oxidized by exposed to roan air for two JOOnths.

was distributed in 5 ml aliquots and frozen at

'!he oxidized media
-200c for later use.
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2.

'1he Macrg:ilage Activators

I.PS fran salnpnella tydlosa 0901 (Difoo, Detroit, MI), obtained in lyqilolyzed form, was rehydrated in HBSS, distr.ibrt:ed into 1 ml
aliquots at a c:xn::entration of 100 u;Vml, arxi stored at -200c until
needed.

Cal A (Difoo, Detroit, MI), obtained

in ctyStalline form,

was also rehydrated in HBSS arxi stored at -200c.

Preparation of~

parvym for use in this assay was the same as that described in sec-

tion B. of this chapter.
3.

'Ihe Macrqilage Motoxicity AssaY

'Ihe methods employed for this assay (37) are JOOdificatians of
the technique originally described by Doe arxi Henson (70) •

Mice were

injected with 1 ml of aged thioglycolate broth, i. p. , arxi sacrificed
by cervical dislocation four

to five days later.

Peritoneal exudate

cells (PEC) were abt:ained by peritaieal lavage with 10 ml of HBSS
conta~

ten units of hepari.Jv'ml (Difoo, Detroit, MI). '1he PECs

were washed once in

HBSS arxi resusperxied at 1. 3

x 106 cells/ml in

carplete RFMI-1640 medium suwlemented with ten percent FBS.

one

hurrlred microliters of the suspensions were plated in 96-well micro-

titer plates.

Nooadherent cells were eliminated after two hours of

incubation by rerooving the culture medium arxi replacing it with 100
ul of fresh RFMI-1640.

After an additional twenty

to twenty-four

hours of incubation, the culture media was again rerooved arxi replaced

with 80 ul of carplete mMI-1640 medium.

'lhe awropriate activators

were then added in 100 ul volumes to each well in quadruplicate.
'!Wenty to twenty-four hours later, 1 x 104 51cr-labeled target cells

were added to each well in a 100 ul volume.

After eighteen to twenty

43
hoUrS, the cultures were centrifug'Ed at 400 x q for five :mirnrt:es.

seventy microliters of culture supernatant were carefully renDVed
frcm each well arxi radioactivity determined usirq the Gamma 4000
gaimna

radiation counter.

control cultures contained radiolabeled

tunor tazqets incubated with nonactivated thioqlycolate-imuced,

Maxill'B.nn possible cellular release of 51.cr was cbtain-

adherent PECs.

ed by

addinJ

NP-40 to control cultures, or by disturl:>irq the pelleted

target cells with rigorous pipettin;J before supernatant harvestirq.

Data are expressed as PSR:
(Mean CfM

PSR == 100 x

in activated well) -

(Mean CfM

in control well)

(Mean CfM NP-40 well) - (Mean CfM in control well)

L.

Lymdloid Cell Proliferative Response
Spleen arxi lYll'Pl oode cell suspensions, processed in the same

manner as described for the cytotoxic T cell assay, were resusperded
in oarplete m:MI-1640 medium suwlemented with two percent Fm.

one

humred microliter aliquots of spleen arxi lYll'Pl oode cells were
plated in 96-well microtiter plates at 2 x ic5 arxi 1 x io5 cells per
well, respectively.
Mitanycin-c inactivated tunor cells were prepared by incubatirq 1 x io7 tunor cells with 25 u;;i of mitanycin-c in one ml of
c::arplete m:MI-1640 medium for one hour.

'1he cells were washed three

times in Ha9S, arxi resusperded in oarplete m:MI-1640 medium with two
percent FBS.

F.ach stin:W.ator cell pop.llation was plated in tripli-

cate at 1 x 105 cells per well in 100 ul aliquots with spleen am
ly:rrph node effector cell pop.llations.

Spleen arxi lyq;il node effector

cells were incubated alone to detennine a basal level of prolifer-
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ative activity.

Duplicate cultures were pl].sed six hours with l UCi

3H-thymidine after two arr:i five days of m:::ubatim.

Cell cultures

were harvested with the cambridge HID autanated cell harvester arxi

radiolabel i.nc:mporatia'l for eadl sanpl.e was determined usin;J liquid
scintillatiai specb:qilatanatry.

Data are expressed as stilllll.atia'l

irrlexes (SI):

SI = Mean cm (Effector Cells+ stinul.ator Cells)
(Effector Cells)

Mean CfM

M.

In Vitro Effect of IIrl on EL-4 Pro1iferation
lD vitro passaged EL-4. lynq;ilana cells were harvested fran cell

culture, washed once in HBSS, resuspenied in catplete REMI-1640
medium with ten percent FBS,

96 well microtiter plates.

am

incubated at 5 x io4 cellsftNell in

Various doses of IIrl, rargin;J fran 0.1

to 25 units of IIrl activity, were added to the t\lllX)r cell micro-

cultures.

All IIrl doses were tested in triplicate.

Proliferative

activity was assessed with a six hour 3H-thymidine pulse after one

am two days of t\lllX)r cell incubation with IIrl.

'!he cultures were

harvested am OOl.lllted as described previously for other 3H-thymidine

proliferative assays.
N.

Determination of Serom Antibody Titers Against the EL-4
IJymphana

1.

Preparation am Fixation of the EL-4 Lysate
EL-4 ascites suspensions were washed three times with saline,

then resuspeOOed in 2. 5 ml of

1 x 107 cells.
oocasiooal

minutes.

o. 5 percent

NP-40 lysis hlffer per

'!he cells were incubated for ten minutes at 40c with

vortexirXJ

followai by oentriflgation at 700 x g for thirty

'!he supematant

was careful.ly decanted with

50 ul of this
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cell lysate added to each well of a flexible 96-well microtiter plate
(Falcon Plastics, No. 3911).
at 37"c ovemight,

allowin.1

'!he lysate was incubated in the wells
the lysate to dry in each well.

'!he cell

lysate was fixed to the wells by the addition of 100 u1 of a 0.02
percent glutaraldehyde (Sigma Chemical

co. st. I.oois,

M'.>) in pxis-

I

P'late b.lffered saline (PBS) at roan tenprature for ten minutes.

'lhe

wells were then washed three times with PBS before they were filled
with a 0.1 percent gelatin (Sigma Olemical
tion in PBS.

co.,

st. I.oois, M'.>) solu-

After sixty minutes of incubation at

roan 't:enq:>erature

the plates were again washed three times with PBS, inverted, drained,
arxi stored dry at 4"c covered with plastic wrap.

2.

Antibody Bin:lirg Assay

mood sa:nples were c:btained fran mice receivin;J variQJS treatment protocol animals by cardiac pmcture.
clot at roan teq:>e:rature for several hours.

'!he blood was allowed to
Serum

was separated by

centrifugation at 700 x g for twenty minutes, decanted,

-2ooC

am

stored at

until needed.
Fifty microliters of each serum sa:nple were added to the EL-4

cell lysate coated microtiter plate wells in a mist chamber arxi
incubated eighteen hours at 4"c.
with 0.1 percent gelatin in PBS

'!he 'Wells were washed six times

am drained. one humred microliters

of a 1:2000 dilution of horse radish peroxidase labeled affinity
purified goat antibody to

100USe

IgA+IgG+IgM heavy

am

light chains

(Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD) was added to

each EL-4 lysate coated well.
roan "terrperature.

'!he antibody was incubated one hour at

'!he wells were then washed ten times with the 0.1
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percent qelatin

in~

soluticn by inversicn, followed by four

washeS with 0.1 percent qelatin

pipet.

o.1

in~ by

ll¥Jl:'e

aspiraticn with a pasteur

After thorcugh drainirq 150 u1 of substrate oonsistirq of,

mM 2. 2 '-Azioo-di (3-ethyl-benzthiazoline sulfonic acid) as sub-

strate am o. lM glycine citrate buffer pH 4. o at 2sOc am o. 02 per-

cent H2~, was

added to each well.

Followirq one hour of incubation

color development of the substrates was measured by optical density
at 405 nm with a MR-600 Microplate Reader (Dynatech Laboratories
Inc. , Alexarrlria, VA) •

'!he antibody titer will be detenn.ined usirq

the ABC50 method described by Mi.men am Farr (203).

c.

A.

Anti-tum:>r activity of

1.

In vivo Sup:>ression of the Eir-4

parwm

Va:cyirg numbers of raiviable

~by

c.

c.

parvum

parvum oells wze admixed with

in vivo passaged Eir-4 lyqilana cells, then injected, i.d., in the
flanks of mice.

In this manner, the bacterial dose required to sup-

press tumr growth was assessed.

Pooled results of two experiments

which yielded similar results, shown in Table 3, Wicate that sup-

pression of tumr growth was deperrlent upon the rrumber of bacteria

injected with the tumr challenge.

umer

these experimental con:li-

tions, optimal protection against the tumr resulted when 2 x 109

c.

parvum cells

c.

parvum was utilized for all further

experiments.

wze admixed with the

lower oonoentrations of

tum:>r challerqe.

'lhis dose of

in vivo tumr protection

c.

parvum proved to be less

effective with 1 x 109 cells p:rot:ectirg fifty-seven percent of the
animals am 1~108 resultirg in only a twenty percent ~ival rate.
Animals which received the tumr challenge without local

c.

parvum

therapy denalstrated no survival.

Animals which survived the initial tumr challenge remained
free of subsequent tumr develcpnent.

'lhese animals were rechal-

lenged with 5 x 103 EU-4 tumr cells thirty to sixty days later.
shown in Table 3, none of these animals survived.
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'lhese results

As
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suggest that no lcn;J-lastirg inm.mity was generated as a consequence
of

c.

parwm treatment of the EL-4 lynphana.
In vitro Macrophage Activation by

2.

c.

parwm

'lbioglyoolate imuced macrophages activated by a forty-eight
hoUrs incubation with heat-killed

c.

parwm dena1strated tullK>ricidal

activity against 5J.cr radiolabeled EL-4

am RBL-5

tum:>r target cells

in a dose-depenjent manner as shown in Figure l, a represenative

exanple of six experiments dena1stratirq similar results.

Previous

work by Wigzell (306) has correlated 5J.cr release fran radiolabeled
tUIOOr targets with loss of cell viability as detennined by trypan
blue dye exclusion.

As little as l x io8 ~ parvum cells/ml 'Were

able to activate peritoneal macrophages to a tullK>ricidal stage, with
increasirq levels of cytotoxic activity peakirg at an activator dose

of l x io9 bacterial cells/ml.
Followirq sixteen hours of incubation with the

c.

parwm

activator, SJ.er radiolabeled EL-4 tullK>r target cells dem:>nstrated no
loss of viability as detennined by trypan blue dye exclusion (see
Table 4).

c.

Tun¥:>r cell viability remained high after incubation with

parvum activator ooncentrations rarqirq f:ran l x ioS to l x iolO

bacteria/ml..

Likewise, I.PS dEm:>nstrated no toxicity to the tUIOOr

cell targets in the ooncentration rarge utilized in the cytotoxicity

assay,

altho.:gh I.PS was cytotoxic to these cells at a c:oncentration

of 100 ug/ml.

'lherefore, release of radiolabel in these experiments

was not due to direct cellular toxicity by the activators in this
system.

'Ihese data dem:>nstrate that

c.

parvum activates macrqilages

to becane tuJIDricidal for experimental lynpianas,

thereby suggestin;J

TABLE 3.

Suppression of the EL-4 Lymphoma by Corynebacterium parvum.a

survival
Primary Challenge
Bacterial
Number

#Survivors/
#Challenged

(%)

Secondary Challenge
x2

#Survivors/
#Challenged

(%)

2 x 109

13/13

(100)

p < 0.01

0/13

(0)

l x 109

8/14

(57)

p < 0.01

0/8

(0)

l x 108

2/10

(20)

N.s.b

0/2

(0)

EL-4 Alone

0/14

(0)

aBacteria (0.1 ml) were admixed with EL-4 cells (0.1 ml) and injected i.d. into the
right flank of each animal.
bN.S., not significant; p> o.os, experiemnts were compared with those for animals
injected with EL-4 alone.
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\0

50

Figure 1.

Effect of in vitro c. paryum activation of thioglyoolate indl1oed ~ on the in:iuction of tullDricidal
activity. Folladrq a 24 hour~ st.ilmJlation with

~ Paryum, 51.cr radiolabeled Eir4 (•) an:l RBir-5 (A)
'b.m¥:>r targets were added to the culture. After 16-18
hairs of incubation the PSR of 51.cr was determined for
each culture. Fac::h value represents the mean PSR of
triplicate cultures ± STD.
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TABIE 4.

Eir-4 ~ Cell Viability Followirg Il"Dlbatiai
With C. parvum am LPS Activators.

AMXlNI'/ml

~(%)

± 5.4
90.6 ± 3.1
86.4 ± 5.1
46.2 ± 10.2
87.4 ± 4.0
92.0 ± 2.4

c.

parvum

1 x iolO

c.

parvum

1 x lo9

c.

parvum

1 x loB

LPS

100 ug

LPS

10 ug

Medium

0

89.6

a2 x lo5 Eir-4 turoor target were in::ubated with activators
in 96-well microtiter plates for sixteen boors.
~iability was determined by trypan blue dye exclusicn.
'!he data are expressed as the mean viability of
duplicate cultures± the st:amard deviaticn.
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that the .in vivo tuoor protective capability of .c..z. parvum ciJsezved in

this experimental system may :be a result of local activation of
macrqil.ages.
B.

In vivo Protective Effect of IL-1 Against the E!c4 IMtJ:hgna

1.

Effects of P388Dl Mac;rg;fulge Derived IL-1
A series of

.in vivo experiments

irduce protective .llmnunity in the EL-4

system.

.Anilllals given the

tTNO groups.

one

9mlp

EL-4/~

were performed with IL-1 to
lynpiana/~ pa:ryum

treatment

parwm admixture were divided into

received no further therapy while the other

group received, i.d., P388Dl macrqnaqe derived IL-1 therapy as descr.ibei in Sectiai G of the Methods ani Materials chapter.

summarizes the results ftan six experiments.

Table 5

~tely

eighty

:percent of the animals in both protocol groups survived the initial

c.hallen:Je.

'lhirty-five to fifty days later, animals which survived

the primaey tuiror challen:Je, were rechallen;Jed with a similar EL-4

tuoor dose with no further therapy.

.Anilllals which received i. p.

injections of IL-1 at the time of the primary tunw:>r c:hallen:Je, showed

a statistically significant enhanced survival rate of 53.5 percent
upon rechallerqe (p<0.02) when oc:mpared by d:rl.-square analysis to

animals not given IL-1.

SUrvivirq animals, given the

EL-4/~

parvum

admixture without IL-1, exhibited a rechallerqe survival rate of 20. 7
percent.

No statistical differences were denalstrated between re-

c.hallen;Jed animals initially treated with the EL-4/C. pa:ryum admix-

ture without IL-1, EL-4 with IL-1 alone, or EL-4 withcAit therapy.
'Ihe survival c:m:ves for these animals followirg the primary

tuoor c.hallen:Je are presented in Figure 2.

.Anilllals receivirg EL-4

TABLE 5.

Suppression of the EL-4 Lymphoma by Corynebacterium parvwn and P388DlY
Macrophage Derived IL-1.a

Survival
secondary Challenge

Primary Challenge
Treatment
Protocol
EL-4 with
parvum
+ MD IL-1

#Survivors/
#Challenged

(%)

#Survivors/
#Challanged

(%)

x2

~

43/53

(81.1)

23/43

(53.5)

p < 0.02

EL-4 with
parvum

29/37

(78.4)

6/29

(20.7)

N.s.b

EL-4 Plus
MD IL-1

7/30

(23.3)

1/7

(14.3)

EL-4 Alone

8/44

(18.2)

1/7

(14.3)

~

aBacteria- (2-x-109 per 0.1 ml) were admixed with EL-4 cells (O.l ml) and injected i.d.
into the flank of each animal. IL-1 was administered i.p. (O.l ml) from day o to
day 9 post-tumor inoculation. A total of 100 units of IL-1 was administered per
animal.
~.s., not significant; p > 0.9, experimental was compared with animals receiving EL-4

alone, IL-1 alone and surviving second challenge.
U1
~
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am c.

paryum or EL-4

sw:vival pattems.

am c.

parvum plus IL-1 showed nearly identical

Animals administered EL-4 alone or EL-4 plus IL-1

therapy exhibited low sw:vival rates of 18.2

am

23.3 percent :respec-

tively, with no statistical difference shown between these sw:vival
rates as determined by chi-square analysis.
SUrvival curves for animals (which had sw:vived the initial
challerge) followin;J a seoaDlly challen;Je with the tunDr are depicted in Figure 3.

Animals which had initially received the EL-4

challerge, alooe or with acxx:apany.in;J IL-1 therapy, showed a rapid
drop in sw:vival to 14.3 percent by thirty days post rec:hallen;Je.

Animals which initially received EL-4

am c.

pazyum, or EL-4

am ~

pazyum plus IL-1, showed an enhanced sw:vival rate until approxim-

ately day forty-two, at which time the animals that had received EL-4

am

~

pazyum exhibited a drq> in sw:vival to a level (20. 7 percent)

not statistically higher I by t test analysis I than animals which had

initially received either EL-4 alooe or EL-4

am

IL-1.

'Ibis data SU}1ests that systemically administrated P388Dl
mamqmge derived IL-1 augmented inm.mity to the EL-4 lynphana such
that a secorxi tunDr challerge did not progressively CJrcM to kill the
animals.

In

contrast, redlallerged mice which received

c.

parvum

trea"bnent without IL-1 dena1strated no statistically enhanced sur-

vival.

Systemically administered IL-1 had no tunDr suppressive

effect without the addition of a local administration of
2.

Effects of Murine

~inant

c.

paryum.

IL-1

An In vivo tunDr protection experiment was perfonned us.in;J

recombinant :murine IL-1 obtained fran Hoffmarm-I.aRoche, Inc.

In this
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Figure 2.

Effect of P388DlY macrqilage derived Ilrl therapy ai
survival follC11lin;J the prilllaey Eir4 tultDr c:hallerge.
Eir4 c:hallerged mice were treated with either c.
paryum (X) I P38801Y macrqi1aq8 derived Ilrl (0) I
c. paryum ard P388DlY macrqilage derived Ilrl Cb), or
no treatment (•). Treatment am tuDDr injectia'l
protocols were administered as described in sectiai G
of the Methods am Materials chapter.
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Figure 3.

Effect of P38801Y macrqbaqe derived IIrl therapy on
survival follOfotlin;J the seoorXlary Eir4 tunDr challen;re.
Mice treated at the time of the primary Eir4 challerge
with either c. parvum (X), P388DlY mac:rqilage derived
IIrl (¢) , c. parwm ani P388DlY mac:rqilage derived
IIrl (A), or no treatment (•), were given a seoord
Eir4 challerge. Treatment ani tmoor injection protocols were as administered as described in section G of
the Methods arrl Materials chapter.
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experiment animals received the primary Eir4 tunor challen;Je with

local

c.

parvum therapy, i.d., plus i.p. therapy, with either 100

units of Jllll"ine reoanbinant IIrl or unstinulated P388DlA oorxlitioned
culture supematants.

challen;Je

'Were

AnilDals which survived the initial bmm'

given a seocni Eir4 challen;Je thirty-five days after
Results fran this trial are

the primary tunr:>r dose was administered.

shown in Table 6.

Eir4 chal.len;Jed animals that received either ~

paxyum plus murine recanbinant IIr-1, or

c.

pu:yum plus unstimulated

P388DlA oorditioned culture supematants deloonstrated similar

sur-

vival rates of 93 ard 100 peroent, respectively, folla.rin:] the
primary tunr:>r challen;Je.

Animals that received the EL-4 challen;Je

withrut therapy all died within thirty-two days (Figure 4).

Follow-

irg the Eir4 recballerge, animals which received systemic recanbinant
IL-1 therapy deloonstrated a 26 .1 percent survival rate, while animals
which received the non-IIr-1 con:t:ainin:; supernatant, all succumbed to
the tunr:>r (Table 6) •

All recballen;Jed animals, that received

c.

paryum therapy plus the unstim.llated P388DlA culture supernatants

rapidly died (within twenty-seven days) ard showed nearly identical
sw:vival patterns with no prolon;iation of mean survival tine when
coopared to animals that received the Eir4 as an initial challen;Je as

detennined by t test analysis (Figure 5) •

In oontrast, animals that

had received II.r-1 up:>n initial challen;Je showed a nm:e gradual. decline in recballerge survival, thereby qeneratirg a markedly prolon;ed survival curve with the last death :recorded at day thirtyseven as shown in Figure 5.

'!he mean recballen;Je survival duration

of 31.3 days for the IIrl treated animals was detennined to be

TABLE 6.

Suppression of the EL-4 Lymphoma by Corynebacterium parvum and Murine
Recombinant IL-1.a

Primary Challenge
Treatment
Protocol

#Survivors/
#Challenged

(%)

Secondary Challenge
#Survivors/
#Challenged

(%)

-~

EL-4 with
parvum
+ IL-1

40/43

(93. 0)

6/23

(26.1)

EL-4 with
parvum
+ Non-IL-lb

14/14

(100)

0/4

(0)

EL-4 Alone

0/10

(0)

0/5

(0)

~

aBacteria (2 x 109 per 0.1 ml) were admixed with 5 x 103 EL-4 cells (O.l ml) and
injected i.d. into the flank of each animal. IL-1 was administered i.p.
(O.l ml) on alternate days from day o to day 9 post primary tumor inoculation.
bNon-IL-1, P388DlA unstimulated conditioned culture supernantant.

°'......
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Figure 4.

Effect of llll.lrine reccmbinant IL-1 therapy on SUl:Vival
follCJWin;1 the primaJ:y EI.r-4 tulror c.hallen;Je. EI.r-4
challen:Jed mice were treated with either c. paryum am
llll.lrine reccmbinant IL-1 (6), C. paryum am P388DlA
unstimulated c:xnlitioned media (~), or no treatment
(•). Treatment am tulror injection protocols were
administered as described in section G of the Methods
am Materials chapter.
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Figure 5.

Effect of llllrl.ne :rec:anbinant IIrl therapy on survival
followin] the secxn3aJ:y Eir-4 tum:>r challerge. Eir-4
dlallcm;ied mice were treated with either c. pazwm am
111.1rine recanbinant nri (A) , c. pazwm am PJssolA
unstinll.ated c:xnlitialed media <<» , or no treat:Jrent
(•) , wre qiven a seocni Eir-4 challen;e. Treat:Jrent
am 'b.mm' injectioo protocols wre as administered as
described in sectioo G of the Methods am Materials
dlapter.
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significantly enhanoed (p < 0.02) when carpared to the 25.2 day mean
survival duration of mice which received the unstinW.ated P388Dl
con:litioned supematant.
'Ihese data deloonstrate that a combination of local adjuvant

therapy (C. paryum), in conjunction with systemic recanbinant IIr-1

administration, resulted in a statistically enhanoed survival duration for rechallen;red animals.

'1hese results are similar

to those

obtained with macrqilaqe derived IIr-1.

c.

In vitro Effect of IL-1

cm the Eir4 lynpigna

Various anamts of IIr-1 were added to actively prolife:ratin;J

in vitro Eit-4 cultures as described in section M of the Methods arxi
Materials chapter.

As shown in Figure 6, fran

o. 75 to 12.5

units of

exogenously added IIr-1 had no deleterious or enhanciIX] effects on the

in vitro proliferative capacity of Eir4 cultures after twenty-four or
forty-eight hoors of irx::ubatiai.
D.

Assessn-ent of Eir4 Reactive Antibody Titers Against the EI.c4

IMN2bana
In Table 7, serum obtained frcm animals which :received the
Eir4 tuioor challen;re either alone, with

c.

parvum. or with

c.

paryum

plus macrophage derived IIr-1, were tested for Eir4 reactive antibody
titers against the Eir4 lyqbana.

It was apparent that no increase

in antibody titers was detected in the sera of mice challen;re4 via
aey of the experimental protocols when tested periodically up to

eighteen days after the initial 'l:ulror challen;re.
tunor via

c.

Mice cured of the

paryum plus IIr-1 therapy also deloonstrated no detect-

able levels of Eit-4 reactive antibody up to 40 days after the tUlOOr

67

Figure 6.

Effect of murine recarribinant IL-1 on the in vitro
proliferation of EL-4 turror cells. EL-4 cells were
cultured with or without M.lrine recombinant IL-1 for
24 ~) ani 48 hours (•) • EL-4 cell proliferation was
determined by cellular 3H-thymidine inco:i:poration as
described in section M of the Methods ani Materials.
Each value represents the mean PSR of triplicate
cultures

± STD.
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TABLE 7.

Serum Antibody Levels Reactive With the EL-4
Lymphoma Following the Primary EL-4 Tumor
Challenge.a
Serum Antibody Titer
DAY POST PRIMARY TUMOR CHALLENGE

TREATMENT
PROTOCOL

DAY 6

DAY 9

EL-4 Alone

<10

<10

~

EL-4 with
parvum

<10

EL-4 with
parvum
Plus MD IL-1

DAY 13

DAY 18

DAY 40

<10

<10

Noe

<10

<10

<10

ND

<10

<10

<10

<10

<1ob

No Treatmentc

ND

ND

ND

ND

<10,25

Hyperimmuned
Against EL-4

ND

ND

ND

ND

370,115,25
<10,<10

~

aserum antibody titer determined by ELIZA as described in
section N of the Methods and Materials chapter.
bAnimals with no visible sign of tumor developmen, forty
days after the EL-4 challenge, were considered cured
of the tumor. Three animals were tested, all with
antibody titers <10.
cNormal C57Bl/6 serum.
dAnimals were repeatedly immunized with mitomycin-c
treated EL-4 tumor cells.
eND, Not determined.
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challenge.

A majority of mice hyperimmunized by repeated injection

with mitamycin-c treated EL-4 tum::>r cells did show an elevated antibody titer to the tum::>r.

'Ihese data i.rrlicate that systemically

administered IIr1 was unable to augment the humoral inunune response
against the Eir-4 lyng;>homa, within the detectable limits of the ELISA
system employed.
E.

Effect of systemically Administered IIr-1 Upon the Number of
Cells Recovered from the Lymph Nodes Draining the Site of the
Eir-4 'I'Ulror Challenge
Animals which received Eir-4 and

c.

parvum or Eir-4 and

c.

pazyu:m. plus IIr-1 were sacrificed at various time periods following

both the EL-4 primacy and secorrlal:y challenge.

'Ihe total number of

lyrrph node cells sequentially recovered from the regional axillai:y

and brachial lyrrph nodes drainiDJ the tum::>r injection site following
the secorrlal:y Eir-4 challenge is presented in Figure 7.

Mice that re-

ceived both tum::>r protection protocols demonstrated marked increases
in recovered lyrrph node cell numbers soon after the Eir-4 rechallenge.
Although, both groups demonstrated increased cell numbers, IIrl
treated animals demonstrated a significantly greater response two and
four days after the rechallenge, when carpared to animals not given
IIr1.

'Ihe lynph node cell numbers in both protocol groups decreased

by day five after the rechallenge, with no differences in cell number

noted between the two groups subsequently.
Initially, organ weights were detennined for lynph nodes

drainiDJ the site of
IIr-1 treated mice.

the primacy tum::>r challenge for IIr-1 and non-

However, at early time points lyrrph nodes were
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Figure 7.

Effect of P388DlY macrophage derived IL-1 therapy on
the lymfilocyte cell mnnber in the lymfil nodes draining
the site of the Eir-4 tumor challenge. Mice treatErl at
the time of the primacy EL-4 challenge with either
c. pa+yum (•) or c. pa+yum plus P388DlY macrophage
derived IL-1 (A), were given a second Eir-4 challenge
35 days after the initial Eir-4 challenge. 'Ihe lymfil
nodes cell mnnber was detennined for lynph nodes
draining the site of the tumor challenge at various
time periods for each group f ollowirg the second Eir-4
tumor challenge. Each value represents the mean lyitpi
node cell number of there mice ± STD.
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too Slt1al.l to assess weights accurately.

total lynph node cell

numbers

To overcome this difficulty,

were obtained for each treatment

protocol animal group in a secorrl series of experiments.

Pooling of

data obtained from both protocols was acc::oirq;>lished by calculating the
percent change of lynph node weight or lYJIP:l node cell number between
mice given

c.

pazyum arrl

c.

pazyum plus IL-1.

Pooled results for

days 4, 8, 13, arrl 17 yielded a percent change of +10%, +6%, -19%,
an:l -3% respectively.

'!his data did not reflect arr:/ marked nodul-

ation of lynph node mass due to IL-1 therapy following the prima:cy
tumor

chall~e.

Only data from animals without tumor were utilized

in these calculations since animals with palpable tumor (generally

detectable at day 12 to 15) developed corresporxlingly enlarged lynph
nodes draining the tumor site regardless of previous treatment (data

not shc::MI'l).

'Ihese results suggest that, while IL-1 therapy did not

modulate gross lYJIP:l node mass following the prima:cy tumor

chall~e,

IL-1 did induce accelerated regional lynph node cell proliferation
andjor the stimulation of lymphoid cell convergence to the regional
lynph nodes draining the site of the tumor

rechall~e

following a

second exposure to the EL-4 tumor.
F.

Effects of systemically Administered IL-1 Upon Splenic arrl
Lymph Node in vitro Correlates of Immunity Directed Against the
EL-4 Lymphoma
In a series of experiments, animals

chall~e

with

c.

were given an EL-4 tumor

pazyum therapy plus either: macrophage derived IL-

1, murine recombinant IL-1, control HSA, or no aocompanying i.p.
therapy.

'Ihese mice were assessed for either splenic or lYJIP:l node
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cytotoxic T cell activity, NK activity, or lymphoproliferative
responsiveness to the EI.r-4 lymphoma, followin:J both primacy arrl

secomary t\lll'Or challenges.
1.

cytotoxic T Cell Activity
As

shown in Table a, it is apparent that spleen arrl lymph node

cells derived from animals uniergoin:J an initial EI.r-4 t\lll'Or challenge
either with the EI.r-4 t\lll'Or alone, EI.r-4 arrl the protective

c.

paryum

therapy, or EI.r-4 arrl c. paryum plus macrophage derived IIr1, demonstrated no detectable T cell cytolytic activity against 51cr radiolabeled EI.r-4 t\lll'Or targets greater than one L.U.

'Ihe lack of lytic

activity by spleen cells was demonstrated by periodic testin:] between
day three arrl day seventeen followin:] the primacy t\lll'Or challenge.
Lymph node cell populations, derived from these animals, were tested
periodically for activity from day eight to day seventeen followin:]
the primacy t\lll'Or challenge arrl showed a similar lack of cytolytic T
cell activity against the EI.r-4 t\lll'Or targets.
Similar results, shown in Table 9, were obtained when lymph
ncx:ie arrl spleen cell populations derived from EI.r-4 rechallenged
animals protected initially with

c.

paryum plus either murine recomb-

inant IIr-1, macrophage derived Ilr-1, or HSA control injection therapy, were tested for cytolytic activity against EI.r-4 targets thirtyfive days after the primacy challenge (day o post rechallenge)

~

Fol-

lowin:J rechallenge with the EI.r-4 lymphoma, the lymph node arrl spleen
cell populations from these groups of animals showed no cytolytic
response greater than one L.U. to the EI.r-4 lymphoma.

TABLE

a.

Effect of macrophage derived IL-1 on Splenic and Lymph Node T Cell cytotoxicity Against the EL-4 Lymphoma Following Primary EL-4 Tumor Challenge.
SPLEEN CELL POPULATIONSa,b

LYMPH NODE CELL POPULATIONSa,c

DAYS POST
PRIMARY
CHALLENGE

EL-4

3

<ld

<l

<l

ND

ND

ND

6

<l

<l

<l

ND

ND

ND

8

<l

<l

<l

<l

<l

<l

10

<l

<l

<l

<l

<l

<l

13

<l

<l

<l

<l

<l

<l

17

<l

<l

<l

<l

<l

<l

EL-4 with
parvum

~

EL-4 with
parvum
Plus IL-1

EL-4

~

EL-4 with
parvum

~

EL-4 with
parvum
Plus IL-1

~

aspleen and lymph node effector cell suspensions represent cells pooled from three
animals sacrificed from each treatment protocol group.
bRadiolabeled EL-4 YAC-1 tumor targets (1 x 104) were incubated with effector spleen
cell populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as
described in the Methods chapter.
cRadiolabeled EL-4 YAC-1 tumor targets (1 x 104) were incubated with effector lymph
node cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four
hours as described in the Methods chapter.
dData are represented as L.U. of activity at ten % specific release per 1 x 106
effector cells as described in section I of the Methods and Materials chapter.
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TABLE 9.

Effect of Murine Recombinant (MR) and Macrophage Derived (MD) IL-1 on
Splenic and Lymph Node T Cell Cytotoxicity Against the EL-4 Lymphoma
Following the Secondary EL-4 Tumor Challenge.
SPLEEN CELL POPULATIONSa,b

DAYS POST
SECONDARY
CHALLENGE

EL-4 with
parvum
+ HSA

~

EL-4 with
parvum
+ MR IL-1

~

EL-4 with
parvum
+ MD IL-1

~

LYMPH NODE CELL POPULATIONa,c
EL-4 with
parvum
+ HSA

~

EL-4 with
parvum
+ MR IL-1

~

EL-4 with
parvum
+ MD IL-1

~

0

<ld

<1

<1

<1

<1

<1

3

<1

<1

<1

<1

<1

<1

6

<1

<1

<1

<1

<1

<1

aspleen and lymph node effector cell suspensions represent cells pooled from three
animals sacrificed from each treatment protocol group.
bRadiolabeled EL-4 tumor targets (1 x 104) were incubated with effector spleen cell
populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as
described in section I of the Methods and Materials chapter.
CRadiolabeled EL-4 tumor targets (1 x 104) were incubated with effector lymph node
cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four hours
as described in section I of the Methods and Materials chapter.
dData are represented as L.U. of activity at 10% specific release per 1 x 106
effector cells as described in section I of the Methods and Materials chapter.
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'Ihese data suggest that IL-1 therapy was not able to elicit
the development of a notable in vitro T cell cytolytic response in
the spleen or regional lymph nodes in animals following the primary
Eir4 tumor challenge nor in cured mice which were treated with IIr-1

am
2.

then exposed to a secorxl tumor dose.
Natural Killer Cell Activity
Repeated periodic assessrrents were made of NK activity of

spleen cell populations derived from animals urrlergoing an initial
Eir4 tumor challenge either with the Eir4 tumor alone, Eir4

paryum therapy, or Eir-4 arrl

c.

am c.

paryum plus macrophage derived IIr-1.

Results of a typical experiment, presented in Table 10, showed a
degree of fluctuation in the amount of lytic activity against YAC-1
tumor targets in tests perfonned from day to day.

However, compared

differences in L.U. between spleen cell populations on individual
days shows no pattern of augmented NK activity as a result of systemic administration of macrophage derived IIr-1.

Results of t test

analysis corrparing the PSR of the 100 to 1 E/I' ratio data points for
the three spleen cell populations tested on each day, established
that no statistical differences in NK activity were seen between
these groups on days three, eight, ten, arrl thirteen following the
primary tumor challenge.
apy or

c.

On day six, animals which received no ther-

paryum therapy with the Eir-4 challenge, demonstrated a sta-

tistically enhanced cytolytic response when compared to mice that had
received Eir-4 arrl

c.

parvum plus IIr-1 therapy.

'!his result was re-

versed on day 17, when the IIr-1 treated mice demonstrated an enhanced
development of NK activity, when compared to animals not given IIr-1.

TABLE 10. Effect of Macrophage Derived IL-1 on Splenic and Lymph Node Natural Killer
Cell Activity Against YAC-1 Tumor Targets Following the Primary EL-4 Tumor
Challenqe.
SPLEEN CELL POPULATIONSa,b
DAYS POST
PRIMARY
CHALLENGE

EL-4

EL-4 with
~ 12arvum

EL-4 with
~ 12arvum
+ IL-1

LYMPH NODE CELL POPULATIONSa,c
EL-4

EL-4 with
12arvum

~

EL-4 with
12arvum
+ IL-1

~

3

3.22d

2.70

2.30

ND

ND

ND

6

2.08

1.91

l . 33

ND

ND

ND

8

3.13

2.74

1.47

<l

<l

<l

10

<l

<l

1.14

<l

<l

<l

13

2.70

3.03

3.33

<l

<l

<l

17

<l

<l

2.00

<l

<l

<l

aspleen and lymph node effector cell suspensions represent cells pooled from three
animals sacrificed from each treatment protocol group.
bRadiolabeled YAC-1 tumor targets (1 x 104) were incubated with effector spleen cell
populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as
described in section J of the Methods and Materials chapter.
CRadiolabeled YAC-1 tumor targets (l x 104) were incubated with effector lymph node
cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four hours as
described in section J of the Methods and Materials chapter. E/T ratios of
25:1 and 12.5:1 only were assayed for the EL-4 alone mice on day eight.
doata are represented as L.U. of activity at ten percent specific release per 1 x 106 ~
effector cells as described in section I of the Methods and Materials chapter.
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NK activity of lynph node cell populations were also determined.

SUfficient cell numbers for assessment of NK activity were

not obtained from the regional lynph nodes drainirg the site of the
tumor challenge until the eight days after the primacy EL-4 challenge.

As shown

in Table 10., NK activity of lynph node cells ob-

tained from animals given the EL-4 challenge alone, or EL-4 with
paryum

c.

or EL-4 with c. paryum plus macrophage derived II.r-1, demon-

strated no detectable NK activity above one L.U. from eight to seventeen

days followirx] the primacy tumor challenge.
Both lynph node and spleen cell populations obtained from

animals survivirx] the initial EL-4 challenge with

c.

parvum plus

either murine recanbinant II.r-1, macrophage derived II.r-1, or HSA therapy, were tested for NK activity thirty-five days after the primacy
challenge (day o post rechallenge), and then on days three and six
followirx] the secon:Jacy EL-4 challenge.

As shown

in Table 11. ,

spleen cells obtained from II.r-1 treated animals demonstrated no lytic
activity greater than one L.U. either innnediately before beirq given
the secorrl EL-4 tumor challenge or on days three and six after the
rechallenge.
Cells obtained from regional lynph nodes drainirg the site of
the tumor rechallenge of these mice were also assessed for NK
activity.

Results of these experiments, also presented in Table 11,

show that the lynph node cell populations obtained from the II.r-1

treated animals were equally unable to develop NK activity greater
than one L.U. up to six day after the secorxi EL-4 challenge was

administered.

Control anilnal.s which received HSA injections along

TABLE 11. Effect of Murine Recombinant (MR) and Macrophage Derived (MD) IL-1 on
Splenic and Lymph Node Natural Killer Cell Activity Against YAC-1 Tumor
Targets Following the Secondary EL-4 Tumor Challenge.

SPLEEN CELL POPULATIONSa,b
DAYS POST
SECONDARY
CHALLENGE

EL-4 with
parvum
+ HSA

~

EL-4 with
parvum
+ MR IL-1

~

EL-4 with
c. :garvum
+ MD IL-1

LYMPH NODE CELL POPULATIONsa,c
EL-4 with
:garvum
+ HSA

~

EL-4 with
:garvum
+ MR IL-1

~

EL-4 with
:garvum
+ MD IL-1

~

0

l.osd

<l

<l

<l

<l

<l

3

<l

<l

<l

1. 63

<l

<l

6

<l

<l

<l

1.90

<l

<l

aspleen and lymph node effector cell suspensions represent cells pooled from three
animals sacrificed from each treatment protocol group.
bRadiolabeled YAC-1 tumor targets (1 x 104) were incubated with effector spleen cell
populations at E/T ratios of 200:1, 100:1, 500:1, and 25:1 for four hours as
described in section J of the Methods and Materials chapter.
cRadiolabeled YAC-1 tumor targets (1 x 104) were incubated with effector lymph node
cell populations at E/T ratios of 100:1, 50:1, 25:1, and 12.5:1 for four hours
as described in section J of the Methods and Materials chapter.
dData are represented as L.U. of activity at 10% specific release per 1 x 106
effector cells as described in section I of the Methods and Materials chapter.
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with the protective

c.

pai:yum

therapy did deloc>nstrate NK activity

greater than one L.U. on days three and six, although in neither case
did this activity exceed two L.U.

'Ihese data irx:lica.te that NK activ-

ity did not appear to be enhanced in

c.

paryum treated animals which

received IIrl, following either the primary or secon:lary tumor challenge.

suggesting that enhancement of NK activity does not appear to

account for the IIr1 tumor protective effect.
3.

Lymphoproliferative Responsiveness
In vitro splenic proliferative responsiveness to Eir4 and YAC-

1 stimulator tumor targets was assessed following a secon:lary Eir4
tumor challenge.

Splenic populations from mice that had sm:vived the

primary Eir4 challenge with the aid of protective

c.

pacyum therapy

plus either control HSA therapy, macrophage derived IIrl therapy or
murine recombinant IIrl therapy were evaluated.

Proliferative re-

sponsiveness was detennined sequentially for these groups of mice on
the day animals received the

secoooary

Eir4 challenge and on days

three and six following the rechallenge.

'Ihe results are presented

for proliferative responsiveness to the Eir4 and RBI.rs lymphoma stimulator cells in Figures 8 and 9, respectively.

Both Figures have

identical Y axis scales to allow easier ccmq;>arisons from one Figure
to the other.

Animals which received macrophage derived IIr1 therapy

demonstrated a lOOdest yet significantly enhanced response to the Eir4
lymphoma (Figure 8) on day three (SI= 3.28) and day six (SI= 4.85).
Such an enhancement was not seen in the II.rl treated animals which
were assessed innnediately before the rechallenge (day o) •

However,

the spleen cells from the same II.rl treated animals did not resporrl
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to YAC-1 tum:>r cells (Figure 9) on days three or six (SI = 0.94 an1
1.33 respectively) when identically derived cell populations were
respondin;J to the EL-4 stimulator cells.

'!his response to the EL-4

ly.rrphoma was shown to be significantly enhanced (p < o. 001) when
corrpared to the responsive to YAC-1 stimulator cells on both days
three an1 six, as detennined by t test analysis.

Rechallenged mice which had received the HSA injections shOINed
a statistically enhanced (p <.001) yet weak proliferative response to
the EL-4 lymphoma (SI = 2.3) three days after the EL-4 rechallenge
(Figure 8).

However, no statistically augmented response (SI = 1.47)

was elicited from HSA treated mice on day six follOINi.rq the rechallenge.

No response to YAC-1 stimulator cells (Figure 9) was noted

for these animals on either day three or day six (SI = 0.81 an1 0.96
respectively).

Although this weak spleen cell proliferative response

to the EL-4 lymphoma was observed three days after the tum:>r rechallenge in HSA treated mice, the splenic proliferative response to the
EL-4 lymphoma, generated by the macrophage derived IL-1 treated
animals, was shown to be even statistically greater (p < 0.002) than
the response produced by the HSA treated animals.
Spleen cells from murine recombinant IL-1 treated animals were
likewise assessed for proliferative responsiveness to EL-4 an1 YAC-1
stimulator cells foll01Ni.rq a secorxia.ry tum:>r challenge.

Results also

presented in Figures 8 an1 9 respectively, were remarkably similar to
those produced by animals which received macrophage derived IL-1.
Recombinant IL-1 treated mice demonstrated a modest yet significantly
enhanced response to the EL-4 lymphoma on day three (SI = 3.11) an1
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Figure 8.

Effect of P388DlY :nacrophage derived IL-1 therapy on
in vitro splenic proliferative responsiveness to EL-4
and YAC-1 tUIOC>r cells following the secorrlary EL-4
tUIOC>r challenge. Mice treated with either c. parvum
plus P388DlY :nacrophage derived II.rl or c. parvum plus
HSA which survived a primaey EL-4 tUIOC>r challenge,
were given a secorxi EL-4 challenge. Spleen cell
populations derived from these two groups of mice were
cultured 48 hours with mitamycin-c treated EL-4 or
YAC-1 stimulator cells.
Spleen cell proliferative
responsiveness to the stimulator cells was determined
by cellular 3H-thymidine incorporation as described in
section L of the Methods and Materials chapter. Each
value represents the mean SI of triplicate cultures
± STD.
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Figure 9.

Effect of murine :recanbinant IL-1 therapy on .in vitro
splenic proliferative responsiveness to EL-4 am YA0-1
tum::>r cells followirq the sec:omary EL-4 tum::>r c:tlal.lerge. Mice treated with either c. parvum plus :mrine
recanbinant IL-1 or c. parvum plus HSA Mlich survived
a primary Eir4 tunDr dlal.lerge, were given a seocni
EL-4 c:tlal.lerge. Spleen cell pop.tl.atioos derived frail
these two 9J:Q1PS of mice were cultured 48 hours with
mitanycin-c treated EL-4 or YA0-1 stinlll.ator cells.
Spleen cell proliferative responsiveness to the stimul.ator cells was determined by cellular JH-thymid.ine
incorporation as described in section L of the Methods
am Materials c:hapter. Fach value represents the mean
SI of triplicate cultures ± STD.

YAC-1 STIMULATOR CELLS
1.0

------------------------------,

5.0

x

w

4.0

0

3:
z

s
0

3.0

:>
2

~

2.0

1.0

0.0

K

<

<

•<<c e<g<><><y

1

DAY 0

IZZJ

MURINE REC-IL-1

re

<

<

1ccc ccnc><><>r

1

DAY 3
DAYS POST R£CHAU.ENCE
~ P38801Y IL-1

re

c

c

1cec;::cnc><><>•

DAY 6

IXE

HSA

O>

°'

87

day six (SI = 3.66) following the Eir4 rechallerqe.
was not seen

'!his response

in the IL-1 treated mice which were assessed inunediately

before the tunv:>r rechallerqe (day O post rechallen;e).

Spleen cells

from the same reoanbinant IL-1 treated animals did oot responi to
YAC-1 tunv:>r targets en either days three or six (SI = 0.86

respectively) •
shown

1.27,

'lbese splenic responses to the Eir4 l}'lllilana were

to be significantly enhanced (p<0.001)

when cxmpared

response to YAC-1 stimulator cells both en days three

once

am

am

to the

six.

again, the proliferative response generated by IL-1

treated animals to the Eir4 lyqilana was statistically greater, both
on day three (p<0.05)

am day

six (p<0.001), when cxmpared to the

weaker response produced by the HSA treated oontrol animals.

Followin;J the initial Eir4 tunv:>r challen;e, as shown in Table
12, no responsiveness was demnstrated by IL-1 treated animals to the
Eir4 antigen in oontrast to the enhanced response seen after the
secoMary Eir4 dlal.lerqe.

days

am

'!his time

oc:m"Se

study, initiated three

eOOing fourteen days after the primary challerqe, detected

no proliferative response of spleen cells from IL-1 treated animals

greater than 1. 63 (seen on day fourteen post rechallerqe) • Anllnal.s
that received the Eir4 dlal.lerqe without treatlllent also failed to
generate a proliferative stimulation Wex to the Eir4 lynpioma

greater than 1. 58 as seen on day seven.
with

c.

Anllnal.s that received Eir4

paryum alone dena'lstrated a weak proliferative response to

the Eir4 antigen (SI = 2.43) on day fourteen followinj the primary
dlal.lerqe.

'!his group of animals failed to generate aey marked

proliferative response SI > 2.0) fran day three to day ten.

TABLE 12. Effect of P388DlY Macrophage Derived IL-1 on the Spleen Cell Proliferative
Response to the EL-4 Lymphoma Following the Primary EL-4 Tumor Challengea.

STIMULATION INDEX
DAYS POST PRIMARY CHALLENGE
TREATMENT
PROTOCOL

DAY 3

DAY 7

DAY 10

DAY 14

EL-4 Alone

o.86 + o.34b

1.58 ± 0.10

0.70 ± 0.22

1.32 ± 0.21

~

EL-4 with
parvwn

0.79 ± 0.15

1.91 ± 0.16

0.97 ± 0.30

2.43 ± 0.11

EL-4 with
parvum
+ IL-1

1.53 ± 0.23

1.17 ± 0.17

1.18 ± o. 39

1.63 ± 0.16

~

aspleen effector cell suspensions represent cells pooled from three animals sacrificed
from each treatment protocol group. Mitomycin-c treated EL-4 lymphoma cells
(1 x 105) were incubated two days with various effector cell populations (2 X 105
cells) in a 0.2ml volume. 3H-thymidine incorporation was determined as described
in section L of the Methods and Materials chapter.
bData are expressed as the mean stimulation index of triplicate cultures ± the
standard deviation.
()I)
()I)
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'Ihese data imicate that both macrophage derived arrl murine

recombinant fonns of systemic Ilrl therapy were able to elicit a
sequential enhan::lement of the splenic proliferative response in EI.r-4
rechallerged animals.

'!his response stron:Jly suggests specificity

for the EI.r-4 tmoor; the tmoor antigen seen by these animals at the
time of IIr-1 treatment.

'!his response was shown to be markedly

strorger arrl mre prolorged than responses generated by control HSA
treated mice.
unlike the enharx::ed proliferative response seen in the spleen

cells fram rechallerged IIr-1 treated mice to mitanycin-c inactivated
EI.r-4 stimulator cells, no detectable increase in responsiveness was
generated in lynphoid cells taken frail regional lyitpl nodes
the tmoor chal.lerge site.

drainin:J

Results obtained for lyitpl node cells, ob-

tained periodically from mice followirg both the primary arrl

secom-

ary EI.r-4 tmoor chal.lerge, are shown in Tables 13 arrl 14 respectively.

seven days after the primary EI.r-4 chal.lerge, a weak proliferative
response (SI == 2.10) was generated in mice that received EI.r-4 with
C. parvum plus macrophage derived Ilrl.

'!his proliferative response

was not seen when later assessed at day ten arrl day fourteen.

Al-

though the !Ir1 treated animals did dem:::>nstrate a weak proliferative

response at day seven, animals that did not receive Ilrl also dem:::>nstrated an equally weak proliferative response to the EI.r-4 stimulator
cells.

'Ihus, !Ir1 treatJnent did not appear to be responsible for

this weak response generated early after the initial tmoor chal.lerge.
'!he response seen in mice treated with
by day ten after the primary chal.lerge.

c.

parvum alone also .declined

90

TABLE 13.

Effect of P388DlY IL-1 on Lymph Node Cell
Proliferative Responsiveness to the EL-4
Lymphoma Following the Primary EL-4 Tumor
Challengea.
STIMULATION INDEX
DAYS POST PRIMARY CHALLENGE

TREATMENT
PROTOCOL

DAY 7

DAY 10

EL-4 Alone

Nob

ND

1.65 ± 0.21

~

EL-4 with
parvum

2.30 ± 0.16C

1.00 + 0.30

1.23 ± 0.11

EL-4 with
parvum
+ IL-1

2.10 ± 0.17

1.10 ± 0.39

1.15 ± 0.16

~

DAY 14

aLymph Node effector cell suspensions represent cells
pooled from three animals sacrificed from each
treatment protocol group. Mitomycin-c treated EL-4
lymphoma cells (1 x 105) were incubated two days with
various effector cell populations (1 X 105 cells) in
a 0.2ml volume. 3H-thymidine incorporation was
determined as described in section L of the Methods
and Materials chapter.
bND, not determined.
CData are expressed as the mean stimulation index of
triplicate cultures ± the standard deviation.

TABLE 14. Effect of P388DlY Macrophage Derived IL-1 on the Lymph Node Cell
Proliferative Response to the EL-4 Lymphoma Following the Secondary EL-4
Tumor Challengea.
STIMULATION INDEX
DAYS POST SECONDARY CHALLENGE
TREATMENT
PROTOCOL

DAY 5

DAY 7

DAY 10

DAY 14

EL-4 Alone

Nob

ND

ND

1.67 ± 0.07

~

EL-4 with
parvum

1.04 ± o.1ac

2.16 ± 0.15

0.89 ± 0.30

1.20 ± 0.14

EL-4 with
~ parvum
+ IL-1

1.73 + 0.11

1.92 ± 0.09

1.11 ± 0.20

1.20 ± 0.17

aLymph Node effector cell
sacrificed from each
· cells (l x 105) were
(l X 105 cells) in a
deacribed in section

suspensions represent cells pooled from three animals
treatment protocol group. Mitomycin-c treated EL-4 lymphoma
incubated two days with various effector cell populations
0.2ml volume. 3H-thymidine incorporation was determined as
L of the Methods and Materials chapter.

l>ffD, not deterained.
cData are expressed as the mean stimulation index of triplicate cultures ± the
standard deviation.
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LYD'Pl node proliferative :responsiveness of macrqilage derived
Ilrl treated animals to the Eir-4 lyqilana, follc::Min;J the secorrlary
turoor challerqe, was assessed.

No pattem of lYD'Pl node prolifer-

ative responsiveness was noted followinJ periodic assessment f:ran
five to fourteen days followinj the Eir-4 :rec.hal.lerqe.

'!he greatest

response generated by these animals in this time pericxi was seen on

day seven (SI = 1.92). However, a statistically similar :response was

also generated by
therapy.

c.

parvum treated animals that were not given IIr1

'lhese data in:iicate that Ilrl did not elicit aey detectable

lYD'Pl node cell proliferative :response to the Eir-4 lyqilana followinJ
either the primary or secorXlary turoor challerqe at the time periods
assessed.

OISCIJSSICN
'1he use of cytokines

in cancer innnunotherapeutic IOOdels has

become increasinqly attractive as the

importance of these intercel-

lular messenger ioolecules beccmes ioo:re arrl ioo:re awaz:ent in both in

vivo arrl in vitro studies.

'1he

lOOOOkine, IIr-1,

was

chosen for study

of inununaoodu.lation of the tunor imm.me :response due to the wide
variety of biological activities associated with this protein (64,
78).

several. lines of

evidence stroRJly suggests that IIr-1 may be

able to positively mdulate the host :response to a neoplastic d1al.lenge.

IIr-1 has been shown to augment

.in vitro inm.me :responses

am

enhancinq the proliferation of T (48,177,192)

by

B lYJl'Plocytes

(124,166,247), either directly or throogh the production of other

ly.rrpiokines such as IIr-2 arrl gamma-INF (94,281).

IIr-1 has been shown

to enhance natural killer cell activity (115,239), oontribute to the
generation of cytotoxic T lYJl'PlOCYtes (281),
production both in

YiY2 (166) am in

am

yiYQ (285).

augment antibody
IIr-1 irduces

mac:rqilage prcduction of :EGE2 (68), arrl is involved in the activation
of macrqilages to becane tunoricidal (240).

IIr-1 has also been shown

to be a chenX>attractant for macrqi'lages (170).
deloonstrated direct cytostatic

am

Finally, IIr-1 has

cytotoxic activity against sane

tunor cell lines (168,235).

Little direct eviden::e exists which inlicates a
fUnctional role for IIr-1 in the host :response to neoplastic disease
93
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or for the use of IL-1 as an inm.motherapeutc agent.

'lherefo:re, IL-

1 has been evaluated in this :researdl to assess the efficacy of IL-1
as an immuncm:xiul.ator in an experimental neoplastic ll¥:del.

In this

lOOdel, IL-1 in oanj\.D'lCticm with local adjuvant therapy, has been

deloonstrated to significantly enhmx:Je the tunDr inm.me response of to
the EI.r4 lyn¢ana.

Initial

in vivo imnamoadjuvant tunx:>r protecticm studies usirg

intradermal injections of heat-killed

c.

parwm admixed with an EI.r4

tun-or challerxJe verified previous "WOrk (183,190) imicatirg that the
use of nonviable bacterial imnunoadjuvant antitunx>r therapy was
effective in protectirg C57Bl/6 mice fran an initial EI.r4 tun-or challerxJe.

As dem::>nstrated previously, the tunx>r protective :response

assooiated with bacterial adjuvanticity was enhanced in a dose dependent manner, with 2 x io9 c. parwm cells enabliDj very high sw:vival

against the EI.r4 tunx>r challe?XJe.

'lhe ability of EI.r4 cells to sur-

vive sixteen hours in in vitro suspensions of

bacterial cells

rcmJin:J

heat-killed~ parwm

in concentration fran 1 x io8 to 1 x iolO

cells without loss of viability ,as shown in Table 2, strongly imicates that the admixed heat-killed
the EI.r4 tun-or cells upon

c.

parvum cells

were not toxic to

in vivo challerxJe. 'lherefo:re, toxicity of

the bacterial inum.moadjuvant utilized was not responsible for the

observed protection.
All C.

parvu!ll

treated animals I which SUJ:ViVed the initial EI.r4

challerxJe am were given a secorxi EI.r4 dose without adjuvant therapy.
As shown in table 3, these :rechalle?XJed mice all succumbed

secom

tunx:>r challerqe.

to the

'lbese :results are in straq aq:reement with

95

previous absezvations which in:licate that highly noninm.mogenic
tunv:>rs, such as the Eir4 lynpiaDa, fail to elicit protective bmm'
immunity in anililal.s cured of a primacy bmm' challen:Je by adjuvanttype inmmotherapy (80,249).

It is ag>arent by viewirq Figure 1 that

~

parvum has the

capacity to activate macrqilaqes to bmm'icidal. activity in a dose
depeOOent

manner.

It is also ag>arent that this activatioo was

JDl-

specific in nature since both Eir4 an:i RBtt-5 bmm' cells were both
lysed by

c.

parvum activated JllaCJ:'qilages.

'lhese results are in

agreement with previous work ~ that the antibmm' effect of
~

parvum

in YiYQ

cm relatively noninummogenic tum:>r is the result of

imnumologically nonspecific mechanisms (294).

'Ihe

c.

parvum an:i I.PS

activators did not decrease the viability of the Eir4 tunv:>r cells
when incubated together wit.halt the presen::ie of the PECs for the dur-

ation of the experiment.

A decrease in ta%get cell viability was

seen only when the I.PS concentration was increased to 100

q or ten

times the maxim.nn anomt reported in these macrq:haqe activation
experiments.

'lhese results suggest that one possible mechanism of

antitunv:>r activity of

c.

c.

parvum in this C57Bl/6 murine 100del is local

parvu:m mediated activation of macrqilaqes leadin;J to tunv:>ricidal

activity against the admixed Eir4 tunv:>r cells, an:i not as a result of
direct toxicity to the injected tunv:>r by the bacterial adjuvant.
'!here is also sufficient evidence to in:licate that

can prime mice for 'INF production (41, 112) •

causes henK>rrtlaqic necrosis of
111,113,316).

DrJUSe

c.

parvum

Serum oontainirq 'INF

an:i human

tunv:>rs in vivo (41,

AbJJDant evidence in:licates that the macrqilaqe is the
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major source of serum 'INF with the dem:>nstration that peritoneal macrophages produce 'INF-like activity after stimulation with emotoxin
(150,184,263).

Recent studies have shown that the tuioor variants

which becane resistant to lysis by activated macrqilages have ac:xpired :resistance to 'INF.

'1bese investigators also dJserved that 'INF-

neutralizirq antibody totally inhibited activated macrqilage mediated
t.uioor cell lysis.

'1bese results alOn:J with the known 'INF producirq

capability of activated macrq:hages st:ronJly suggests that the

~

pazyum adjuvant therapy given EL-4 c.hallen;ed mice may activate

macrqi'lages leadin;J to the production of 'INF.

'Ihus iniicatirq a

nonspecific antitum:>r macrqilage mediated mechanism. which lead to the
destruction of the primary tuioor.
In rechallen;Je experiments which enpl.ayed systemic treatment

with macrqilage derived IL-1 oanbined with the local administration
of

c.

paryum, a marked enhancement in rechallen;Je SU?.Vival rates

(53.5 percent) was seen in IL-1 treated animals. A significantly
lower percentage of animals (20.5) which

received~

paryum therapy

without IL-1 survived a similar rechallen;e. Smvivirq animals that
received only IL-1 therapy follCMirq the initial tuioor c.hallenge were
also rechallen;ed.

'1bese animals demonstrated a rechallenge survival

rate statistically similar to animals which
apy alone.

received~

paryum ther-

'lherefo:re, it appears that macrqilage derived IL-1 was

able to enhance rechallen;e survival only in oonjl.lllction with local

c.

parvum therapy.
In similar

experiments utilizirq murine reoanbinant IL-1, a

very high proportion of animals survived which received the EL-4
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tum::>r challerge admixed with

c.

parvum, whether they received the

111.Jrine reoanbinant IL-1 or the P388DlA culture supematants.

Upon

rechallerge of survivors fran each treatment group there was again an
increase in survival rates amn:J mice that had received IIrl when
oarpared to mice given the control P388DlA culture supernatants.

Although the difference in survival rates between these two animal
treatment groups was not statistically significant at p <

o.os,

the

prolorqed survival cuzve produced by the reoanbinant IIrl treated
mice imicated there was a an antitum::>r effect produced by the :reoanbinant mlecule.

statistical analysis verified the OOserved enhaooe-

ment of survival duratioo (p < O.Ol) in the reoanbinant IL-1 treated

mice.

SUrvival curves, shown in figure

s,

generated by rect\alletY;Jed

mice that received the control P388DlA culture supernatants were
essentially identical to control animals that received an initial
tum::>r challerge without therapy.

It therefore appears that :reoan-

binant IL-1 therapy was effective in generatin;J an antitum::>r response
against the Eir4 rechallerge in oonjuootion with local

c.

parvum

adjuvant therapy.
In experiments utilizin;J macrqilage derived IL-1 no differe-

nces were awarent in survival rate of animals which received IL-1
alone or in oonjunction with

c.

parvum when oarpared to the cor.res-

porrlin;J group of animals not receivin;J IL-1, nor did IL-1 extern the

survival time of these animals.

Only followi.rg a seconjazy tum::>r

challerge was a significantly enhanced survival rate noted for IL-1
treated animals, 'Whereas an enhanced survival duration was noted for
animals treated with recanbinant IL-1.

'Ibis d::>seJ:ved antitum::>r
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activity noted in IL-1 treated anilllal.s followirq the seccn:i tunor
c.hallen;Je was associated with a marked increase in the number of
lynp-iocytes in the lyitpl nodes drainin;J the site of the tunor c.hallen;Je.

'!he altered lynphocyte distribution seen in the lyitpl nodes ·

drai.nirg the site of the Eir-4 rechallen;Je of IL-1 treated animals,
suggests that these l}'ltiil nodes may well have hartx>red lyqiloid cells
~·to

the Eir-4 tunor.

Eir-4 specific serum antibody titer was the initial illummolog-

ical parameter assessed in a series of in

~

experiments.

tJrrler

the corditions of the experiments performed in this study, there did
not appear

to be aey production of detectable antibody against the

Eir-4 lynpiana in IL-1 treated anilllal.s within the first several weeks

followiz:g the tunor c.hallen;ie.

IL-1 treated mice considered cured of

the primary Eir-4 c.hallen;ie also failed to elicit a detectable Eir-4

specific antibody response 35 days after the tunor challen;ie.
Unlike man, the

ra?X]e

of target cells susceptible to lysis by allo-

geneic leukocytes lttben sensitized with antibody is very restricted.
M.lrine t:a?:qet cells sensitized with anti-IA antibody are generally
unharmed by

IOOUSe

leukocytes, as determined by the chranium release

assay, althalgh. the possibility of lon:J-term damage has not been
ruled out (19).

'!he lack of aey significant IL-1 imuced antibody

titer against the Eir-4 lynt;ilana, canbined with the generally poor
sensitivity of murine cells to antibody deperdent cellular cytotoxic
ity (19) , makes this an unlikely mechan:l.sm acx:nmtirq for the antitunor activity associated with IL-1 treatment.
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EI.r-4

specific T cell nwediated cytotoxicity, was also shown not

to be enhanced by the administration of IL-1.

'lhe irduction of cyto-

toxic T cells in the lynqil nodes arxi spleens of mice treated with or
without IL-1 was assessed in this system, followirg either the primary tum::>r challe.DJe or after animals cured of the initial challen;Je

received a secon:1aJ:y tum::>r challe.DJe.

Cytotoxic T cells directed

against the EI.r-4 l:ynpnna producirg cytotoxic activity greater than
one L. u. was not obseJ:ved in arr:t of the treatment protocol animals
includirg the animals given IL-1.

'!his data, taken together with the

obseJ:ved lack of augmented hun:>ral .inum.mity in IL-1 treated mice,
suggests that the augmentation of antitum::>r activity seen in these
animals may have resulted frau the generation of naispecific antitum::>r effector mechanisms.
Although recent eviderx::e imicates that IL-1 nay enhance NK
activity of large granular lyq;.hocytes (IGis) (115,239), there was no
apparent in::rease in NK activity after the primary tum::>r challe.DJe.
'lhese results were seen for both spleen arxi lynqil :rX>de cell pcpila-

tions in

c.

parvum treated animals given either macrqilage derived or

recanbinant IL-1, when oarpared to animals 'Which received EI.r-4 alone
or EI.r-4 admixed with

~

parvum.

Splenic NK activity observed for

each of the various treatment groups of mice followinq the primary
tum::>r challe.DJe, as expressed in lytic units, ~to fluctuate
fran day to day.

However, the results for the different treatment

groups within each day's experiment showed less fluctuation with no
pattern of arr:t significant irx:reased or decreased levels of .NK activity for IL-1 treated animals.

Very low levels of NK activity (less

100
than one L. u. ) were roted for lynqil ncxie cell pc:p.ll.atioos of ~

parn.nn plus IL-1 treated animals as well as ooutrol animals that

received Eir-4 alone or EL-4 admixed with
treatment did

~

parvum.

'lhus, IL-1

not appear to augment the NK responsiveness of mice

after the initial d'lallen:Je.

'Ibis is not surprisin;J oonsiderin;J the

lack of enhanced sm:vival of IL-1 treated mice follarln;J the initial
't:unDr c.hal.len;re.
Assessment of spleen arxi lynqil ncxie cell NK activity, follow-

in;J the Eir-4 rechallen:Je of animals treated with

local~

parvum

therapy plus either reoanbinant IL-1 or macrophage derived IL-1,
dem:>nstrated very low levels of NK activity.

received

c.

Control animals which

pazyum therapy plus HSA injectioos showed similarly poor
'!he lack of IL-1 enhanced NK activity may have

NK responsiveness.

been due to the low dosage of IL-1 utilized in this system.

More

recent evidence suggests that BRM-in:iliced increases in NK activity in
other organs such as the liver is partially due to an increase in IGL

cell mnnbers which ooours by a ccanbination of IGL proliferation arxi

an influx of

IGis

via the blocxi (32,125,179).

FUrt:her investigation

has suggested that the hyporesponsiveness of NK activity

which is

in:iuced in the blocxi arxi spleen by repeated administratiai of sane
BRMs, may by partially due to a redistributicm or diversicm of NK

cells fran those sites (288).

'lherefore, the possibility remains

that IL-1 treatment may irxieed have in::reased NK activity in this

system, but at sites not relevant to those tested in this dissertation research, e.g., the localized lynqil nodes drainirq the tUIOOr
site arxi the spleen.
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Splenic popll.ations fran Eir4 rechallaged mice cured of the
initial tunor chal.len;ie with the cx:mbination

c.

paryum plus either

:recanbinant or macrqi1age derived P388DlY IL-1 therapy

in the

presen::ie

ltt'ere

irx::ubated

of EL-4 stimJ]ator cells, am assayed for prolifer-

ative responsiveness to the tunm'.

No proliferative responses ltt'ere

noted in splenic populations ci:>tained fran mice prior to the EL-4
However, lyqila-proliferation did cxx:ur in spleen

tunor rechallerge.

cell taken f:ran mice several days after the seoord exposure to tunm'
antigens for the secxni time.

Proliferative responsiveness to the

tum:>r was d:lserved in spleen cell taken fran mice up to six days

after the EL-4 rechallen;ie.

'!he same spleen cell pc:pllatians fran

IL-1 treated animals which respaOOed to the EL-4 stinul.ator cells did

not respom to the

~iate

YAC-1 stinul.ator cells.

Similarly

rechalleI'.ged control anhnal s which survived the initial Eir4 chal.lerge with the aid
injections

ltt'ere

of~

parvum therapy in oambination with HSA

unable to respord as stron;Jly to the Eir4 cells three

days after the rechallerge, am not at all six days after the secom
1:unm' chal.lerge.

Spleen cells f:ran these animals

ltt'ere

likewise not

able to resporxi to the YAC-1 stinul.ator cells.
'!his IL-1 augmented proliferative response may well be a significant inilcator pointinJ to the role of IL-1 in the capacity as an
antitunor agent (240) • studies in other syn;Jeneic tunor JOOdel. systems have shown stron;J correlations between acquisition of

cutaneoos

delayed-type hypersensitivity :reactivity, mac:rqMge migration inhibition, am lyq;bocyte blastogenesis to tmoor antigens (194) •. Alaq
with the good oorrelation between these activities, the responses
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were shown to be tuiror-line specific an:l dose depement (194) •

'Iherefore, this enhanced splenic response observed in IL-1 treated
animals points to a possible tuiror specific response capable of
augmentirg a variety of antitumr mechanisms.

'1hese responses may be

initiated by migrato:r.y inhibition (170) an:l activatioo of nonocytes,
leadin:J to enhanced antigen presentatiai.

An enhanced presentatioo

of EL-4 antigen may in tum lead to the irxiuctiai of IL-2 or ganmainterferai.

'1hese BRMs are both capable of anti-tunm' activity, an:l

further activatin;J !nm.me processes via the lyqilokine cascade (83) •

'llle generatiai of an enhanced tumr specific response to the

EL-4 lynphana in the spleens of IL-1 treated animals whicil received a
seoorxi tuiror challerqe Wicates earlier IL-1 therapy at the time of

the initial c.bal.lerqe may have irxiuced systemic mdul.ation of the

imnrune system.

Iack of proliferative responsiveness after the

initial c.bal.lerqe may have been due to the ve:r.y low inm.mogenicity of
the EL-4 tuiror (183,190).

'lbere is also the possibility that a t:uioor

irxiuced sua;>ressive state, as seen in other systems (79,224) may have
developed in these mice, thereby not allowirq the detection of activ-

ated cells potentially responsive to the t:uioor.

'llle lack

of~

detectable in vitro augmentation of tuiror specific effector flmctions
in lynphoid populations of IIr-1 treated animals, alon;J with the
enhanc.ed proliferative response noted in IL-1 treated, EL-4 rec.hal.-

len;Jed animals, suggests that the EL-4 responsive lyqtloid cells may
be enhancin;J another antituiror mechanism.

Since the tuiror specific

proliferative responses noted in spleens of IL-1 treated mice failed
to generate ~ detectable enhanced tumor specific effector cell
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functions, the enhanced survival suggests that DJ-1 may be lOOdul.atirg
the :inunune system leadllg to a nonspecific mechanism of tunor control
by the murine host.

Recent studies have shown that lynpiokine activ-

ated killer cells (IAK) are capable of destroyin;J a wide spectrum of
murine

am human tunor

cell lines in vivo

am

in vitro (81) •

'!he

.in

vitro developnent of IAK cells requires the incubation of lyqiloid
cells in the presence of DJ-2 (105), therefore, this type of activity
would not have been detected by .in vitro assesmrents in this study.
DJ-1 treated mice dem::>nstrated an enhanced lynpJOid proliferative
response in the spleen, an area 'Well separated fran the site of the

tunor challetXJe. '!his activatiai followirg a seoormry exposure to
the EU-4 t.uioor st:nn:Jly inplies lyqiloid OZ"gan production of DJ-2,

distant fran the site of tunDr challerge.

It has been dem::>nstrated

in mice that DJ-2 administ:ratioo results in the in vivo qeneration of

IAK activity (215) • '1hus the likely augmentation of DJ-2 production
followirg a secxni exposure to the tUioor at a site distant frail the
tunor suggests a generalized :response, possibly leadllg to the irxiuction of IAK cell activity. Since irduction of IAK activity is associated with lyqilocyte proliferation, this greater number of lyitpiocytes seen in the lYJIPl nodes drai.nin;J the site of the tunor chal-

letXJe imicates possible DJ-2 mediated proliferation
IAK activity.

Al~

am

irduction of

this :mechanism of tunor cell killin;J is not

tunor specific in nature, antigen irduction of DJ-2 may 'Well have
:resulted in an antigen specific manner, as imi.cated by the in vitro
tunor specific splenic proliferation seen in DJ-1 treated mice after
the EU-4 rechalletXJe.
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'lhe lack of an enhanced proliferative response by lymph node

cells cbtained fran IIrl treated mice followi.rq the secaOOary tum:>r
challenge may have been a result of low percentage of macrophages
detected in the reqional lymph node cell ~atioos followi.rq the

i.d. injection of c. paryum.

Without sufficient m.nnbers of macro-

phages in the in vitro incubation culture, the JOOdest proliferative
responses noted in the splenic cultures may not ocx:ur due to the lack
of a critical number of antigen presenti.rq cells in the lymph node

cultures.

'!here is also the possibility that a high proportion of

EI.r-4 reactive lynphoid cells responsible for :meroory irrluction to the
tum:>r may have migrated frail the tumr site to the spleen followi.rq
the primary tumr challen:Je.

'1he possibility also exists that the

massive trawi.rq of lyq;ilocytes in the reqicmal lyqil nodes due to
the c. paryum injectioo may have diluted Eir-4 reactive lyitp1ocytes to
the point that they 'Wall.d not be detected in the thymidine inool:por-

atian assay at the cell ooramtratian utilized.

'!his

~

also

leads to the possibility that an elon;iated time frame of testi.rq
after the secaOOary tumr challe?XJe may have allowed the Eir-4 reac-

tive cells to proliferate to the point of detectioo.
Speculation as to why splenic proliferative responsiveness was
seen inc.
~ pa.tVUm

pa.tVUm

plus IIrl treated mice am not in mice given only

may partially be explained by the events seen in other

tum:>r JOOdels.

Many

reports have shown that suppressor T cells are

generated in response to growth of a variety of imnumogenic tum:>rs
(220) •

In the P-815 tum:>r system studied by Robert North, mice de-

velop Ly 1-2+ T cells capable of tum:>r specific lysis of P-815 target
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cells .in vitro, ard also capable of

regress~

a P-815 tun-or in the

early stages of developnent established in qamna-irradiated mice
(224) • 'lbe developnent of this early cytolytic response quickly
abates as a

oonseqwnJe

of the progressive developnent of!¥ 1+2-

Sl.JR)ressor T cells which wre capable of inhibiti?XJ the expression of
passively transferred inmunity against an established.

Because the

EI.r4 lyntfilana is regarded as a weakly inm.mogenic tunDr, the time
required to generate a detectable inm.me response may be prolon:JE!d
such that the developnent of S\JR)ressor T cells followirg the primary

c.hallen;Je may prevent the in:iuction of a :response sufficient to allow
the develq:ment of .imm.mological menmy.

However, IL-1 treated

animals which survived the primary EI.r4 challen;e were able to generate a IOOderate in vitro splenic proliferative response to EI.r4 stimulator cells soon after a secxni tunDr challen;Je, suggesti.n;J these
mice had responied to the tun¥:>r durirq the primary challen;Je ard
developed menmy as imicated by the splenic proliferation to EL-4

tun¥:>r t:az'qets followirq the
ca~

secorn

tun¥:>r

chall~.

Evide:ooe imi-

Ilrl as an up regulator _for T helper cells ('lff) .in vitro while

inhibi~ the

generatial of T SUJ;PreSSOr cells {Ts) {75,78) suggests

this mechanism of action may account for the proliferative activity

seen in the IL-1 treated mice.

Whether ('lff) is directly enhanced or

(Ts) is inhibited alla.dD:j greater expression of {'lff) has not been
elucidated. 'I.be ability of IL-1 treated animals in this study to
proliferate in response to Eir-4 targets followin:;J the

seoom tunDr

c.hallen;Je imicates IL-1 may have enhanced the ('lff) pcp.ll.ation
responiir¥J to the tunm' _at the time of the initial challen,;Je or
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inhibited the qeneration of (Ts) to a degree, thus allc:Min;J the
developnent of mem:>:cy to the tuloor.

Upon

rechallen;e the IL-1 treat-

ed animals were then able to generate a proliferative response sooner

am with

greater intensity then anilllals not given IL-1 or follc:Min;J a

prima:cy challenge.
the prima:cy

am

'Ihe results of splenic proliferation followinJ

seoozxJa:cy tuloor challenge distinctly show the type of

pattem one would expect if this mechanistic scenario was followed.
'Ihe IL-1 treated animals del.oonstrated a strcn;Jer

am mre p:rol0D1ed

response to Eir4 targets follc:Min;J the secaXJary tuloor challenge,

while the mice not treated with II.rl showed a significantly weaker

am

shorter response.

lD vivo antit.lm:>r effects of human recanbinant IL-1 alP1a,
without the aid of other oorrespon:iin:;J adjuvant therapy have been
reported against several inm.mogenic nurine bm:>r cell lines (33).
An

intra-tuloor (i. t.) sin;Jle injection of a ve:cy large dose of IL-1

(2.5 x 105 units) was required to successfully regress a seven day
old palpable Meth A sarcana tmoor.

Intramuscular (i.m.)

am

i.v.

therapy proved less suooessful, with protective :results attained only

follc:Min;J seven daily injections at 2.5 x 105 units of IL-1 per
injection.

Intravenoos therapy at even higher doses did not lead to

protection against the Meth A bmm'.

Despite the large IL-1 doses

enployed by these investigators, they surprisin;Jly reported no sign
of macrosc:q>ic inflamnation at the site of the injectiC11S.

Similarly

high, i. t. , doses of IL-1 afforded mice protection against seven day
old Bl6 melanana turoors, while even higher i. v.
showed no protective efficacy.

am

i. m. IL-1 doses

Several conceivable mechanisms may :be
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:responsible for the high efficacy by the i.t. rcute.

IL-1 may: have

direct cytotoxic effects against the tun¥:>r cells, act directly on the
tunm' cells so as to facilitate cytolysis by I.GIB, act as a cheDD-

tactic factor for Da'lOCYteS, anj/or augment ioonocyte bmoricidal
activity (240).
IL-1 has been deDK:>nstrat.ed to have .in vitro cyt:ostatic as well

as cytotoxic (168,235) effects on several transfonned cell lines,
suggestinq a possible direct

develqnent.

Direct

.in

.in vivo therapeutic effect against tumr

yj,tro cytolysis of A375 human melanana

am

IB29 murine fibroblast cell lines was detected with reoanbinant IL-1
c::cn:::entratiaw as lOlrl as 0.125 units of IL-1 per ml, with lytic
activity peak:in:J at between cme

am

eight units per. ml.

cytostatic IL-1 dose for the same cell lines was

o. 5

'!he minimal

units per ml,

with the effect peaJd.n; at between two to four unitsjml.

'!he IL-1

serum levels required to achieve in vitro inhibitory effects may well

have been reached with the .in vivo IL-1 protocols used in this stOOy,

oonsiderin] that 10 units of IL-1 were administered per mouse per
injection.

However, at these relative reoanbinant IL-1 doses,

between 1 to 12.5 units per ml, no significant in vitro proliferative

inhibitory activity was c:i'JServed against Eir-4 lyitplana cells by
recanbinant murine IL-1.

Nor

was any

activity noted by the Eir-4 cells.

enhaB:::ement of proliferative

'lhe maximal

.in YiY'.Q IL-1

dosages

attained in these miCl'OOlltures were greater than the irdi.vidual

dosages injected into mice reoeivi.n;J IL-1 therapy.

S.bnilar results

were obtain for Meth A bmm' cell in vitro resistance to IL-1.

'1hese

cells were also not susceptible to .in vitro incubation with high

108

doses of the human reoanbinant II.r-1 alpha (M. Yamada, personal canmunication) • Heix::e, II.r-1 did not delronstrate

arr:t direct .in Yim

antitunbr activity against the EL-4 iynpiana utilized in this study
or against tum:>r suooessful.ly treated in other work.
As shown in figuniS 4 arxl 6 respectively, neither :reoanbinant

or P388DlY macrophage derived II.r-1 therapy, without protective
pazyum therapy, was effective at

leadin:J to animal death.

Taken

suwressin:J

c.

EL-4 tumr pl.'Ogl:eSSion

together with the

.in vitro

it appears unlikely that .in vivo administered II.r-1 had

results,

arr:t direct

antitunx:>r effect upon the intradeJ::mally injected EL-4 tum:>r cells
used in this study.

II.r-1 has also been :reported to have the capacity to enhance
m::mocyte tumricidal activity via a EGE2 mediated mechanism (240) •

II.r-1 ag;>arently augments the tumricidal activity

enhancin;J the production of

~,

of~

by

which in tum is responsible for

m::mocyte irxiuction of cytolytic activity (236) •

since i. t. injection

of II.r-1 was the mre successful route of administration in the Meth A
arxl Bl6 lOOdels, arxl II.r-1 did not inhibit these cell lines at high

.in

vitro concentrations, this II.r-1 mediated mechanism might better
explain the obseJ:Ved antitumr effect.

'lhe m::mocyte chelooattractant

ability of II.r-1 might potentiate this mechanism against the tun-ors,
sinply by
site.

increasin:J

the number of bmoricidal cells at the tun-or

However, as previously discussed for the direct II.r-1 antitum:>r

activity of II.r-1, this mechanism also appears unlikely to have been
an inportant factor

oontri.b.Itin:J

against the EL-4 tumr.

to the protection of C57Bl/6 mice

'!his assllllption can be readied for several
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reasons.

Firstly, IL-1 therapy was ineffective against the primary

EL-4 tunDr challerge, the time at which this mechanism would nost
likely be effective against the tunw:>r.

seccnny, IL-1 was injected

i.p. in protection protocols against the EL-4 tunw:>r, therefore, there
is little reason to suspect these injections would cause an iIX:rease

in nonocytejmacrq:i1age cell numbers at the tunw:>r site.
'!he ability of reoanbinant IL-1

allila to protect against the

weakly inum.mogenic oolm 26 adenocarcinana when treated with similar
doses of reoanbinant IL-1 therapy (219) was mt as dramatic as that

mentioned for the inum.mogenic Meth A.

Althcu;Jh a significant de-

crease in tunw:>r mass was noted twenty-Q'le days follc:71li.nJ the bmm'
challerge, tunw:>r q.cowth in these animals accelerated, eventually
causi.rg death in these animals at approximately the same time as the
untreated control animals.

'lherefore, IL-1 was \.ll'lable to cure

animals of a non-inum.mogenic tunw:>r.
Followi.rg IL-1 treatment, mice cured of the initial Meth A
saroana were able to reject a redlallen]e with the same tunDr.

In

viert1 of the ooncurrent devel.qment of inma.mity in mice protected
against inum.mogenic tunw:>rs, it is possible to suggest that IL-1
lOOdulated tunw:>r specific mechanisnVs lead to the destJ::uction of
inmnmogenic tunw:>:rs.

Al~

these authors have suggested that IL-1

is lNOrkin] in their system by inlirect antitunw:>r mechanisms, no in
vitro assessments of inm.mological parameters associated with antitunw:>r activity have been ccniucted to verify these assunptions.

Also

the IL-1 dosages required to obtain effective cure ratios in their
system were only three

to four fold urrler the

IDso

dose for naive
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mice, suggesting the developnent of in vivo cellular toxic effects
resulti.rg frc:an these doses (19).

FUrtheim:>re, specificity of this

tumr imm.mity was not detennined, since smvivin;J animals -were not
rechallerqed with a tuJoor cell line other than that used for the
prilnaey challen;Je (M. Yamada, personal cammmication).

'lherefore,

the mechanism of IL-1 mediated antitumr effects at these large doses

have yet to be explained.

Although in vivo tuJoor protection studies showed that the

llllrine reoanbinant IL-1 statistically enhanced the smvival duration
of EL-4 rec:hal.len;Jed mice, the increased smvival rates d::>se:rved for
IL-1 treated anjnels t.hen cxmpared to non-IL-1 treated animals was

not sufficient to determine a statistical difference.

'1here are sev-

eral possible explanatioos for not d:Jsezvin:] statistical differences

in smvival rates in these

.in yiYQ reoanbinant

IL-1 protection

studies.

'lhe possibility that the recanbinant mlecule is not as biologically active as the mac:r:qilaqe derived IL-1 employed for study in
this dissertation research.

'Ihe recent p.irification of reoanbinant

am disor biologically derived am

fonns of IL-1 has stirred speculation about the similarities
similarities dem:>nstrated by mnocyte
recombinant IL-1.

'Ihe biological activity of

thfa llllrine reoanbinant

IL-1 isolated by Peter I.anedioo (the same soorce utilized for the

in

vivo studies presented in this dissertation) ·has been reported to be

pyrogeniC, causes hypozinoemia am leukocytosis I am d.eroonstrates in
vitro IAF activity (219).

Hor.\lever, the same authors foum that

recombinant IL-1 alJ;i'la was not capable of

increasin:J

energy experd-
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iture or protein catabolism or anabolism.

'!be reoanbinant fonn of

IL-1 also failed to increase the acute piase proteins (291).

'!be

pyrogenic effect of the nurine reoanbinant !Ir1 was also fooni to be
delayed in ooset, although, the effect was eventually as potent as
the naiocyte derived IIrl (282).

'lherefore, it appears that the

recombinant molecule is not identical to the monocyte derived IL-1
'Whose biological activities have been extensively outlined

past.

in the

It is very possible that the recanbinant IL-1 molecule repre-

sents a pure protein expressed by one gene while the monocyte derived
II.rl may represent a family of proteins each responsible for separate
If this is the case, it is

of overlappirx] biological activities.

possible that the anti'tl.lmr effects of host or macrqilage derived
IL-1 may act though

mre than one specific mechanism,

am

that these

effects may lead to aalitive or syne:tg'istic anti'tl.lmr activity.
When workirq with a reoanbinant mlecule, there is al.so the

possibility that lower level of activity associated with that :reoanbinant mlecule is due to partial denaturatiai or in:::on:ect :renaturation.

'Ibis does seem \.ll'llikely, however, since the recambinant ml.e-

cule does retain many of the biological activities associated with
biologically derived IIrl.
AnOther precaution VU.ch must be assessed when usirq :reoan-

binant materials derived frail L. coli is the potential of en:iotoxin
contamination or reactivity to the reoanbinant protein storage bl:ffer

(in this case guanidine hydrodlloride).

In vivo analysis of reactiv-

ity to a similar concentration of a nonreoanbinant IL-1 recanbinant

protein, made in E. QQl.i

am p.irified

in an identical manner to the
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11¥:>USe

recanbinant IL-1, caused no significant increase in any of the

biological parameters assessed in Dllrine systems (219).
negative results were obtained

men

fer was also tested in this system.

Similarly

the guanidine hydrochloride buf'Ihe recanbinant protein

am

buffer concentration (0.008 M guanidine hydrochloride) tested in that
system was over forty times greater than the concentrations which

were injected with the reoanbinant IL-1 in experiments enployed for

this research.

'lherefore, the recombinant IL-1;

am not potential

contaminatin:;;J errlotoxin, bacterial prot.eins, or bufferirg reagents;
appear to be responsible for the enharx::ed anti'b.uoor activity observed

in this system.
Although reoanbinant IL-1 appeared to be less active in this
system accordirg to statistical analysis of su:r.vival rates, there is

the possibility that other biological response lOOdifiers in the

macrophage derived IL-1 sanples may be involved in p:roducirg additive
or synergistic anti'b.uoor effects.

'Ihe eviderx:le produced in this

research does not SUR;>Ort the idea of additive antit.um:>r effects of
other potential BRMs in the macrqilaqe derived IL-1 oontaini.rq culture supematants, since no antitum:>r response was reflected in the

su:r.vival data.

control animals treated systemically with unsti:au-

lated macrophage culture supematants died followin;J EL-4 rec:hallerge
while a significant number of animals that received IL-1 treatment
were able to su:r.vive.

Fllrt:henoore, the su:r.vival curve generated for

these control animals was no different frau animals that received a

primary EL-4 'b.uoor challen:Je without the aid of any therapy, suggestirg that other BRMs in the macrqi'lage derived culture supematants
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were solely responsible for the a\¥]lDE!l\ted antitunm' effects.
'1hese results

effects by
line.

nr1 am

do rx>t eliminate the possibility of synerqistic

other BRMs produced by the P388Dl macrophaqe cell

Granulocyte-Macrophaqe Colony stinlll.atin;J Factor (Gt-CSF), a

macrophaqe product, has been fann to be produced by cell lines
established fran myelcmn:x:ytic leukemias (175).

It was rx>t sur-

prisin3' when work c::axpleted in Rita Yourg' s lal::Joratory denalstrated
that CSF was fann to be in the P38801Y, IIrl oontainin;i culture

supematants (Rita Yourg, persaial. CXllllllnication, data rx>t shown) •
'!be ability of this BRM to stim.Jlate cell division,

the number of fuootionally mature grarrul.ocytes

am ultimately

am mac:rqil21ges

avail-

able to the host for effector or accessory cell fuootion, may allow a
100re effective response to occur in response to the EU-4 tunm' chall~e.

'Ibis is a distinct p:>ssibility an:i, if true, may account for

the significantly augmented survival rates rx>t seen solely with the

:murine reoanbinant material.

'lbere is also the possibility that

further experimentation with larger groups of animals may allow the

expression of statistical differences in survival rates between the
different treatment groups which were rx>t

awarent

in these st\.dies.

An alternative or synerqistic mechanism of acticn which may

help account for the enhanced IIrl
turoor system revelves

aroom

a~tion

of inmmi.ty in this

the observation that IIr1 administraticn

elicits radioprotective capabilities in the :murine system (222).
Many bacterial agents, such as BOO, IPS, nuramyl dipeptide

have radioprotective effects

am

am glucan

are potent irducers of IIrl, known

to elicit radioprotective effects if delivered before irradiaticn
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(314).

Al.though the exact basis for this protective effect has not

been clearly established, it has been postulated that these effects

are a result of heloopoietic enhancement by IIrl, since previous work
has in:licated that cells in the late

s

i;ilase of the cell cycle are

:mre resistant to irradiatiai dmnaqe (279).

'lhe capacity of IIrl to

initiate the irxiuctiai of the a cascade of lyq;hokines sudl as CSF

am

IIr2 may lead to the develcpuent of various lYllliloid cells by

imucirg hematopoietic progenitor cell populaticms into the

s

i;ilase

of the cell cycle, thereby llx::reasirg the rrumber of potential antitunor reactive lynpiocytes or mnocytes.

As described earlier,

macrophage derived IIr1 was :mre effective in protectirg mice fran
the second tunor challerge.

'lhis effect may have resulted frail

synel:9istic activities of IIrl with other lynpioJdnes associated with
macrophage ooniltioned medium.

As mt:e earlier, CSF

associated with the macrqi'lage derived IIr1.

was

shown to be

'!he synel:9istic activ-

ity between these two lOOl'lOkines may have resulted in nmilizatiai

am

developnent of either IAK effector cell or Eir-4 reactive helper T
cell populatiais, leadi.n;J to an enhanced level of protectiai noted in
the macrophage IIr-1 experimentation.

In contrast, the reoanbinant

IIr-1 without the associated CSF or other macrophage m::>nokines was
ally able to prolong survival duratiai while the macrophage product
was able to enhance survival.

If irrleed, IIrl

am

other macrophage

products acted synel:9istically against the Eir-4 tunor, IIrl a~
to be the main factor in this activatiai process.

'lhis is ~'

since mice which received P388DlA macrophage ooniltioned culture
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medium contai.ninj CSF, but, little or no IL-1 denrmstrated no antitunvor activity, while purified IL-1 did p:rolorq survival.
In view of the results obtained for this dissertation it is

ai;pmmt that IL-1 is capable of m::dul.atirq the 'b.m¥::>r inunune :response

generated against the weakly inunogenic Eir4 lyqilal\a, in a system
where no previous p:rotecti~ response had been seen against a

ary t:uioor c.h.al.lerqe.

Althalgh IL-1 had no disoernal:>le

secom.-

in vivo pro-

tective effect against the primary Eir4 t:uioor c.h.al.lerqe, IL-1 was
able to m::dul.ate the response to the t.uioor, enablirq an enhanced
population of mice to respcni 100re successfully against a seoord
c.h.al.lerqe.

'lhis IL-1 in:iuoed antit.uioor activity was effective only

when IL-1 therapy

was provided in conjunctiai with the protective

parvum adjuvant therapy.

'!he enhanced protective effect observed

against the primary Eir4 c:hallerqe appears to be a result of

parvum mediated

(162).

~

a~tion

~

of macrophage tunvoricidal activity

'!he enhanced number of lynpioc::ytes observed in the regional

lymi;il nodes of IL-1 treated animals followirq the seconi Eir4 t.uioor
c.h.al.lerqe, st:rorqly suggests that the lyqiloid population, originally
recruited to the lYll'Pl -nodes drainirq the tuloor site by the subcutaneous adjuvant injection (201), were m::dul.ated by IL-1.

IL-1 's

imnumoadjuvant activity (285) may have allowed the ll1l.lrine lynpiocytes
to respond to the tuloor antigens 100re.rapidly and effectively before
antigen rerocwal..

At the same time IL-1 's ability to induce hemato-

poietic progenitor cells (222) may have also increased the number of
potential lynphoid effector cells available for recruibnent to the
t.uioor site.

'!he Eir4 specific splenic proliferation seen in IL-1
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treated anllnals again suggests lynphocytic involvement, possibly in

effector an:t;or helper capacity.

'!he lack of detectable Eir-4 specif-

ic htn00ral or cellular antitmoc>r mechanisms such as, augmented serum
antibody titers or T cell cytotoxicity against the Eir-4 lymphoma,

suggests the potentiation of non-specific antitmoc>r mechanisms by
IL-1.

No detectable increase in NK activity, was noted in IL-1

treated animals.

However, an alternate non-specific mechanism which

would be an effective means of

destroyfn.1 the Eir-4 tmoc>r is the

developnent of IAK cells, which demonstrate in vitro lytic activity

against an extremely wide raIXJ8 of b.noors (81).

erative response to the Eir-4 tumr strcn.1ly

'lhe splenic prolif-

~

splenic am

possibly systemic lyn;iloc'Jtic pl.'Oductian of IL-2 (83,140), the BRM
necessary to generate effective IAK activity .in vivo (105) •

'lhe

largest arxi IOOSt prolonged proliferative response to Eir-4 follc::iwin]
the secon:3ary tmoc>r c.hallen;ie was seen in IL-1 treated animals,

suggestfn.1 the possible irnuction of this effector mechanism in IL-1
treated mice.

'lherefore, the IL-1 treated mice 'Walld convert the

enhanced tmoc>r specific proliferative response to the non-specific,
IAK mechanism, for b.noor eradication.

Although interleukin 1 (IL-1) has been shown to :function as an
innm.mological adjuvant in defined antigenic systems, there is little
evidence suggestin;J a protective role for IIrl in neoplastic dis-

eases.

'lhis investigation de:rronstrates that intraperitoneal (i.p.)

injection of macrophage derived IL-1 significantly enhanced inununity
of C57Bl/6 mice to the weakly inmunogenic EL-4

Mice given

lyq:hana.

an intradennal injection of the Eir-4 lyqnana admixed with
showed a high survival rate.

c.

parvum

Aniinals identically c.hal.len;Jed, wt

given i.p. macrophage derived IL-1 (100 units/animal) showed similar
survival.

However, upon subsequent reohallen;Je of these mice with

the EL-4 lynphana alone, the gra.ip given IL-1 denrAnstra.ted a markedly

enhanced survival rate (p < 0.01) cxmpared to the groop not qiven

IL-1.

Mice given murine reccmbinant IL-1 in conjunction

with~

parvum, denalstrated a statistically enhanced survival duratioo
following a secomary t.unx:>r c.hal.len;Je (p <
animals given

c.

paryum wit.halt IL-1.

o. 02)

when oarpared to

SUrvival rates of mice c.hal.-

lerqed with the EL-4 turor an:i administered only i.p. IL-1 (macroP1age derived an:i murine reccmbinant) showed no statistical differ-

ence to animals c.hal.len:Jed with the turor alone.

'1hese results

strol'X}ly suggest that IL-1 may :function to augment turor inununity
when administered systemically, in conjunction with local administ-

ration of

c.

paryum.
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lD vitro assessment of EL-4 specific antibody titer, natural
killer cell activity, am EL-4 specific cytotoxic T cell activity of
IL-1 am non-IL-1 treated mice denonstrated no detectable IL-1 imuced augmentation of these hunr>ral or cellular effector cell functions.
A marked iJx:rease in lYJl'Pl node cell rrumbers obtained f:ran

lyqil nodes drainin;J the bnoor dlallerqe site of IL-1 treated mice
following the secorX!aJ:y bnoor dlallerqe, suggested a lyirphoid cell
migration or a lynphoproliferative response in these lyqil nodes
followirg the

secom

EL-4 tumr dlallerqe.

Both macrqilage derived

(p < 0.001) or murine recombinant (p < 0.05) IL-1 treated mice also

dem::>nstrated an enhanced EL-4 specific lynphop:roliferative responsiveness in their splenic cell pop.llations.

'!his IL-1 iniuced,

splenic proliferative response, oambined with the lack of

8rf;1

obser-

ved IL-1 iniuced tumr specific effector cell response, stron:Jly

suggests an IL-1 enhanced tumr specific augmentaticm of a non-tumr
specific mechanism of tumr killirg •
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